[S02DA03, antipyrine, The risk or severity of renal failure and hypertension can be increased when Antipyrine is combined with Cyclosporine.]
[A14AA02, stanozolol, The risk or severity of liver damage can be increased when Stanozolol is combined with Cyclosporine.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be decreased when combined with Cyclosporine.]
[J01GA01, streptomycin, Cyclosporine may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Cyclosporine.]
[L01AD04, streptozocin, Streptozocin may increase the immunosuppressive activities of Cyclosporine.]
[L04AA27, fingolimod, Fingolimod may increase the immunosuppressive activities of Cyclosporine.]
[M03AB01, succinylcholine, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Cyclosporine.]
[A02BX02, sucralfate, Cyclosporine may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Cyclosporine may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The risk or severity of renal failure can be increased when Sulfadiazine is combined with Cyclosporine.]
[J01ED01, sulfadimethoxine, The risk or severity of renal failure can be increased when Sulfadimethoxine is combined with Cyclosporine.]
[A07AB03, sulfaguanidine, The risk or severity of renal failure can be increased when Sulfaguanidine is combined with Cyclosporine.]
[J01ED02, sulfalene, The risk or severity of renal failure can be increased when Sulfametopyrazine is combined with Cyclosporine.]
[J01ED07, sulfamerazine, The risk or severity of renal failure can be increased when Sulfamerazine is combined with Cyclosporine.]
[J01EB03, sulfamethazine, The risk or severity of renal failure can be increased when Sulfamethazine is combined with Cyclosporine.]
[S01AB01, sulfamethizole, The risk or severity of renal failure can be increased when Sulfamethizole is combined with Cyclosporine.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cyclosporine.]
[J01ED05, sulfamethoxypyridazine, The risk or severity of renal failure can be increased when Sulfamethoxypyridazine is combined with Cyclosporine.]
[J01EC03, sulfamoxole, The risk or severity of renal failure can be increased when Sulfamoxole is combined with Cyclosporine.]
[J01EB04, sulfapyridine, The risk or severity of renal failure can be increased when Sulfapyridine is combined with Cyclosporine.]
[M04AB02, sulfinpyrazone, The serum concentration of Cyclosporine can be decreased when it is combined with Sulfinpyrazone.]
[J01EB01, sulfisomidine, The risk or severity of renal failure can be increased when Sulfaisodimidine is combined with Cyclosporine.]
[S01AB02, sulfisoxazole, The risk or severity of renal failure can be increased when Sulfisoxazole is combined with Cyclosporine.]
[M01AB02, sulindac, The risk or severity of renal failure and hypertension can be increased when Sulindac is combined with Cyclosporine.]
[N05AL01, sulpiride, Cyclosporine may increase the neurotoxic activities of Sulpiride.]
[N03AX03, sulthiame, The therapeutic efficacy of Sulthiame can be decreased when used in combination with Cyclosporine.]
[A10BC01, glymidine, The risk or severity of renal failure can be increased when Glymidine is combined with Cyclosporine.]
[M01AX04, apazone, The risk or severity of renal failure and hypertension can be increased when Azapropazone is combined with Cyclosporine.]
[L01BB02, mercaptopurine, Mercaptopurine may increase the immunosuppressive activities of Cyclosporine.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Tacrine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Cyclosporine.]
[N05CD07, temazepam, Cyclosporine may decrease the excretion rate of Temazepam which could result in a higher serum level.]
[L01CB02, teniposide, Teniposide may increase the immunosuppressive activities of Cyclosporine.]
[R03CC03, terbutaline, The risk or severity of hypertension can be increased when Cyclosporine is combined with Terbutaline.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Cyclosporine.]
[G03BA03, testosterone, The risk or severity of liver damage can be increased when Testosterone is combined with Cyclosporine.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Cyclosporine.]
[S03AA02, tetracycline, The metabolism of Cyclosporine can be decreased when combined with Tetracycline.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftaroline fosamil.]
[N05AE05, lurasidone, The metabolism of Lurasidone can be decreased when combined with Cyclosporine.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Cyclosporine.]
[N04BC07, apomorphine, The metabolism of Cyclosporine can be decreased when combined with Apomorphine.]
[L04AX02, thalidomide, Thalidomide may increase the immunosuppressive activities of Cyclosporine.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Cyclosporine.]
[P02CA02, thiabendazole, Cyclosporine may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[L01XX41, eribulin, Eribulin may increase the immunosuppressive activities of Cyclosporine.]
[R06AD03, thiethylperazine, Cyclosporine may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[L01AC01, thiotepa, Thiotepa may increase the immunosuppressive activities of Cyclosporine.]
[L01BB03, thioguanine, Tioguanine may increase the immunosuppressive activities of Cyclosporine.]
[N05CA19, thiopental, The metabolism of Cyclosporine can be increased when combined with Thiopental.]
[N05AB08, thioproperazine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Thioproperazine.]
[N05AC02, thioridazine, The metabolism of Thioridazine can be decreased when combined with Cyclosporine.]
[N05AF04, thiothixene, Cyclosporine may increase the neurotoxic activities of Thiothixene.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Cyclosporine.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Cyclosporine is combined with Moxisylyte.]
[N05AL03, tiapride, Cyclosporine may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, The metabolism of Ticlopidine can be decreased when combined with Cyclosporine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Cyclosporine.]
[P01AB02, tinidazole, Cyclosporine may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Cyclosporine may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Cyclosporine may decrease the excretion rate of Tolazamide which could result in a higher serum level.]
[M02AX02, tolazoline, Cyclosporine may decrease the antihypertensive activities of Tolazoline.]
[V04CA01, tolbutamide, Cyclosporine may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, The risk or severity of renal failure and hypertension can be increased when Tolmetin is combined with Cyclosporine.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Cyclosporine.]
[N06AF04, tranylcypromine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Tranylcypromine.]
[N06AX05, trazodone, The metabolism of Trazodone can be decreased when combined with Cyclosporine.]
[L01XF01, tretinoin, Tretinoin may increase the immunosuppressive activities of Cyclosporine.]
[S01BA05, triamcinolone, Triamcinolone may increase the immunosuppressive activities of Cyclosporine.]
[C03DB02, triamterene, The risk or severity of hyperkalemia can be increased when Triamterene is combined with Cyclosporine.]
[N05CD05, triazolam, The metabolism of Cyclosporine can be decreased when combined with Triazolam.]
[C03AA06, trichlormethiazide, The risk or severity of renal failure can be increased when Trichlormethiazide is combined with Cyclosporine.]
[A16AX12, trientine, Cyclosporine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Trifluoperazine.]
[S01AD02, trifluridine, Trifluridine may increase the immunosuppressive activities of Cyclosporine.]
[N05AD02, trifluperidol, Cyclosporine may increase the neurotoxic activities of Trifluperidol.]
[N05AA05, triflupromazine, Cyclosporine may increase the neurotoxic activities of Triflupromazine.]
[S01BA09, clobetasone, The risk or severity of adverse effects can be increased when Clobetasone is combined with Cyclosporine.]
[S01BA10, alclometasone, The risk or severity of adverse effects can be increased when Alclometasone is combined with Cyclosporine.]
[D07AC02, fluclorolone, Fluclorolone may increase the immunosuppressive activities of Cyclosporine.]
[R03BA07, mometasone, Mometasone may increase the immunosuppressive activities of Cyclosporine.]
[A03AA05, trimebutine, The metabolism of Trimebutine can be decreased when combined with Cyclosporine.]
[R06AD01, trimeprazine, Cyclosporine may increase the neurotoxic activities of Alimemazine.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be decreased when combined with Cyclosporine.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Cyclosporine is combined with Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Cyclosporine.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Cyclosporine.]
[J01FA08, troleandomycin, The metabolism of Cyclosporine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Cyclosporine.]
[C09CA09, azilsartan medoxomil, The risk or severity of hyperkalemia can be increased when Azilsartan medoxomil is combined with Cyclosporine.]
[M03AA02, tubocurarine, The therapeutic efficacy of Tubocurarine can be increased when used in combination with Cyclosporine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Cyclosporine.]
[L04AA26, belimumab, Belimumab may increase the immunosuppressive activities of Cyclosporine.]
[L01FX04, ipilimumab, Cyclosporine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The serum concentration of Cyclosporine can be increased when it is combined with Vandetanib.]
[R02AA14, oxyquinoline, Cyclosporine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Abiraterone can be decreased when combined with Cyclosporine.]
[A10BH05, linagliptin, The serum concentration of Cyclosporine can be increased when it is combined with Linagliptin.]
[J05AP03, boceprevir, The serum concentration of Cyclosporine can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Cyclosporine can be increased when it is combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Cyclosporine can be decreased when combined with Rilpivirine.]
[S01AA28, vancomycin, Cyclosporine may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[L04AA28, belatacept, Belatacept may increase the immunosuppressive activities of Cyclosporine.]
[N03AX21, ezogabine, The therapeutic efficacy of Ezogabine can be decreased when used in combination with Cyclosporine.]
[B01AF01, rivaroxaban, The metabolism of Cyclosporine can be decreased when combined with Rivaroxaban.]
[R03AC18, indacaterol, The metabolism of Indacaterol can be decreased when combined with Cyclosporine.]
[B01AC24, ticagrelor, The serum concentration of Ticagrelor can be increased when it is combined with Cyclosporine.]
[C08DA01, verapamil, The serum concentration of Cyclosporine can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Cyclosporine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, Vinblastine may increase the immunosuppressive activities of Cyclosporine.]
[C04AX07, vincamine, Cyclosporine may decrease the antihypertensive activities of Vincamine.]
[L01CA02, vincristine, Vincristine may increase the immunosuppressive activities of Cyclosporine.]
[L01CA03, vindesine, Vindesine may increase the immunosuppressive activities of Cyclosporine.]
[B03BA01, vitamin B12, Cyclosporine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.]
[A11HA03, vitamin E, The serum concentration of Cyclosporine can be decreased when it is combined with Vitamin E.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Cyclosporine.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Cyclosporine is combined with Xenon.]
[C03BA10, xipamide, The risk or severity of renal failure can be increased when Xipamide is combined with Cyclosporine.]
[J05AF01, zidovudine, Zidovudine may increase the immunosuppressive activities of Cyclosporine.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be decreased when combined with Cyclosporine.]
[J05AE02, indinavir, The metabolism of Cyclosporine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The therapeutic efficacy of Levetiracetam can be decreased when used in combination with Cyclosporine.]
[L01EC01, vemurafenib, The risk or severity of renal failure can be increased when Vemurafenib is combined with Cyclosporine.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Pamidronic acid.]
[L01FX05, brentuximab vedotin, Brentuximab vedotin may increase the immunosuppressive activities of Cyclosporine.]
[M05BA05, tiludronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Tiludronic acid.]
[B06AC02, icatibant, Cyclosporine may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The serum concentration of Cyclosporine can be increased when it is combined with Crizotinib.]
[R03DC01, zafirlukast, The metabolism of Cyclosporine can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Cyclosporine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[S01XA15, ascorbic acid, The serum concentration of Cyclosporine can be decreased when it is combined with Ascorbic acid.]
[M05BA06, ibandronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of nephrotoxicity can be increased when Trovafloxacin is combined with Cyclosporine.]
[N05AE04, ziprasidone, The metabolism of Cyclosporine can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Cyclosporine can be decreased when combined with Drospirenone.]
[V03AC02, deferiprone, Cyclosporine may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[L04AA34, alemtuzumab, Alemtuzumab may increase the immunosuppressive activities of Cyclosporine.]
[N02BA01, aspirin, The risk or severity of renal failure and hypertension can be increased when Acetylsalicylic acid is combined with Cyclosporine.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the immunosuppressive activities of Cyclosporine.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Cyclosporine.]
[J01DH04, doripenem, Cyclosporine may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The metabolism of Atenolol can be decreased when combined with Cyclosporine.]
[L03AB11, peginterferon alfa-2a, Peginterferon alfa-2a may increase the immunosuppressive activities of Cyclosporine.]
[L01FA01, rituximab, Rituximab may increase the immunosuppressive activities of Cyclosporine.]
[J02AC03, voriconazole, The serum concentration of Cyclosporine can be increased when it is combined with Voriconazole.]
[M03AC04, atracurium, The therapeutic efficacy of Atracurium can be increased when used in combination with Cyclosporine.]
[S01FA01, atropine, Cyclosporine may decrease the excretion rate of Atropine which could result in a higher serum level.]
[M01CB03, auranofin, Cyclosporine may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Cyclosporine.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Cyclosporine.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Cyclosporine.]
[H02AB11, prednylidene, Prednylidene may increase the immunosuppressive activities of Cyclosporine.]
[B03XA04, peginesatide, Cyclosporine may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may increase the immunosuppressive activities of Cyclosporine.]
[L04AX01, azathioprine, Azathioprine may increase the immunosuppressive activities of Cyclosporine.]
[L01BC05, gemcitabine, Gemcitabine may increase the immunosuppressive activities of Cyclosporine.]
[J01DF01, aztreonam, Cyclosporine may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Bacitracin.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Cyclosporine.]
[M03BX01, baclofen, Cyclosporine may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Cyclosporine.]
[L01FX02, gemtuzumab ozogamicin, Gemtuzumab ozogamicin may increase the immunosuppressive activities of Cyclosporine.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Cyclosporine.]
[G04BD12, mirabegron, The metabolism of Mirabegron can be decreased when combined with Cyclosporine.]
[L01XG02, carfilzomib, Carfilzomib may increase the immunosuppressive activities of Cyclosporine.]
[V03AX03, cobicistat, The metabolism of Cyclosporine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Cyclosporine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Cyclosporine can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, Bosutinib may increase the immunosuppressive activities of Cyclosporine.]
[L04AA31, teriflunomide, Teriflunomide may increase the immunosuppressive activities of Cyclosporine.]
[A02AA05, magnesium silicate, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium silicate.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Octopamine.]
[L04AA22, abetimus, Abetimus may increase the immunosuppressive activities of Cyclosporine.]
[H02AA01, aldosterone, Aldosterone may increase the immunosuppressive activities of Cyclosporine.]
[L01EX05, regorafenib, The serum concentration of Regorafenib can be increased when it is combined with Cyclosporine.]
[N05CA04, barbital, The metabolism of Cyclosporine can be increased when combined with Barbital.]
[D02BA02, octinoxate, Cyclosporine may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Cyclosporine can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, Bendamustine may increase the immunosuppressive activities of Cyclosporine.]
[N04BD02, rasagiline, The risk or severity of hypertension can be increased when Cyclosporine is combined with Rasagiline.]
[C08CA13, lercanidipine, The metabolism of Cyclosporine can be decreased when combined with Lercanidipine.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Cyclosporine.]
[N03AX22, perampanel, The metabolism of Cyclosporine can be increased when combined with Perampanel.]
[L04AA29, tofacitinib, Tofacitinib may increase the immunosuppressive activities of Cyclosporine.]
[N02CC03, zolmitriptan, The risk or severity of hypertension can be increased when Cyclosporine is combined with Zolmitriptan.]
[G04BD10, darifenacin, The metabolism of Darifenacin can be decreased when combined with Cyclosporine.]
[V09IX04, fluorodeoxyglucose F18, Cyclosporine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of hypertension can be increased when Cyclosporine is combined with Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Cyclosporine.]
[H01CB05, pasireotide, The bioavailability of Cyclosporine can be decreased when combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Cyclosporine.]
[V08CA11, gadofosveset, Cyclosporine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, Ponatinib may increase the immunosuppressive activities of Cyclosporine.]
[B01AF02, apixaban, The metabolism of Cyclosporine can be decreased when combined with Apixaban.]
[A16AX08, teduglutide, Cyclosporine may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C10AX12, lomitapide, The serum concentration of Cyclosporine can be increased when it is combined with Lomitapide.]
[J04AK05, bedaquiline, The metabolism of Bedaquiline can be decreased when combined with Cyclosporine.]
[C04AX11, bencyclane, The metabolism of Bencyclane can be decreased when combined with Cyclosporine.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Cyclosporine.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Cyclosporine can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of renal failure can be increased when Bendroflumethiazide is combined with Cyclosporine.]
[L04AX06, pomalidomide, Pomalidomide may increase the immunosuppressive activities of Cyclosporine.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Cyclosporine.]
[N02BA10, benorilate, The risk or severity of renal failure and hypertension can be increased when Benorilate is combined with Cyclosporine.]
[N05AD07, benperidol, Cyclosporine may increase the neurotoxic activities of Benperidol.]
[A10BK02, canagliflozin, The serum concentration of Cyclosporine can be increased when it is combined with Canagliflozin.]
[L04AX07, dimethyl fumarate, Dimethyl fumarate may increase the immunosuppressive activities of Cyclosporine.]
[J01MA15, gemifloxacin, The risk or severity of nephrotoxicity can be increased when Gemifloxacin is combined with Cyclosporine.]
[M04AB03, benzbromarone, Cyclosporine may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[A12CC09, magnesium orotate, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium orotate.]
[S01AE07, moxifloxacin, The risk or severity of nephrotoxicity can be increased when Moxifloxacin is combined with Cyclosporine.]
[A06AX06, tegaserod, The metabolism of Tegaserod can be decreased when combined with Cyclosporine.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Cyclosporine.]
[J02AX04, caspofungin, The risk or severity of adverse effects can be increased when Cyclosporine is combined with Caspofungin.]
[L03AA12, ancestim, Cyclosporine may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of renal failure can be increased when Celecoxib is combined with Cyclosporine.]
[N02CC02, naratriptan, The risk or severity of hypertension can be increased when Cyclosporine is combined with Naratriptan.]
[C10AC04, colesevelam, The serum concentration of Cyclosporine can be decreased when it is combined with Colesevelam.]
[L04AA18, everolimus, The serum concentration of Everolimus can be increased when it is combined with Cyclosporine.]
[A12CC05, magnesium aspartate, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium aspartate.]
[N04AC01, benztropine, The metabolism of Benzatropine can be decreased when combined with Cyclosporine.]
[L01EC02, dabrafenib, The serum concentration of Cyclosporine can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of renal failure and hypertension can be increased when Benzydamine is combined with Cyclosporine.]
[L01EE01, trametinib, Cyclosporine may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Cyclosporine.]
[V09AX05, florbetapir F-18, Cyclosporine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[L01EB03, afatinib, The serum concentration of Afatinib can be increased when it is combined with Cyclosporine.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Cyclosporine.]
[J05AJ03, dolutegravir, Cyclosporine may decrease the excretion rate of Dolutegravir which could result in a higher serum level.]
[C08EA02, bepridil, The metabolism of Bepridil can be decreased when combined with Cyclosporine.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Cyclosporine.]
[A10BJ03, lixisenatide, Cyclosporine may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[A05AA03, cholic acid, Cyclosporine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.]
[C02KX04, macitentan, The metabolism of Macitentan can be decreased when combined with Cyclosporine.]
[L01EL01, ibrutinib, Ibrutinib may increase the immunosuppressive activities of Cyclosporine.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Cyclosporine.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be decreased when combined with Cyclosporine.]
[N03AF04, eslicarbazepine, The metabolism of Cyclosporine can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The serum concentration of Cyclosporine can be increased when it is combined with Simeprevir.]
[J05AP08, sofosbuvir, Cyclosporine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Cyclosporine.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Cyclosporine.]
[C01CA27, droxidopa, The risk or severity of hypertension can be increased when Cyclosporine is combined with Droxidopa.]
[C07AB04, acebutolol, The metabolism of Acebutolol can be decreased when combined with Cyclosporine.]
[N05CH03, tasimelteon, The metabolism of Cyclosporine can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Cyclosporine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, Apremilast may increase the immunosuppressive activities of Cyclosporine.]
[L02BG02, formestane, The metabolism of Cyclosporine can be increased when combined with Formestane.]
[S03BA03, betamethasone, Betamethasone may increase the immunosuppressive activities of Cyclosporine.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be decreased when combined with Cyclosporine.]
[V03AB34, fomepizole, Cyclosporine may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, Cyclosporine may decrease the antihypertensive activities of Bethanidine.]
[C10AB02, bezafibrate, The risk or severity of renal failure can be increased when Cyclosporine is combined with Bezafibrate.]
[L04AC11, siltuximab, Siltuximab may increase the immunosuppressive activities of Cyclosporine.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Cyclosporine.]
[B01AC26, vorapaxar, The serum concentration of Cyclosporine can be increased when it is combined with Vorapaxar.]
[L04AA33, vedolizumab, Vedolizumab may increase the immunosuppressive activities of Cyclosporine.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Cyclosporine.]
[L01XH04, belinostat, Belinostat may increase the immunosuppressive activities of Cyclosporine.]
[L01EM01, idelalisib, Idelalisib may increase the immunosuppressive activities of Cyclosporine.]
[R03AC19, olodaterol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Olodaterol.]
[L03AB13, peginterferon beta-1a, Peginterferon beta-1a may increase the immunosuppressive activities of Cyclosporine.]
[V08AA01, diatrizoic acid, Cyclosporine may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[V08AA04, iothalamic acid, Cyclosporine may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[N05CM19, suvorexant, The serum concentration of Cyclosporine can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Cyclosporine.]
[J01XA05, oritavancin, The metabolism of Cyclosporine can be increased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Dihydrostreptomycin.]
[N05AA04, acepromazine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Acepromazine.]
[A06AH03, naloxegol, The serum concentration of Naloxegol can be increased when it is combined with Cyclosporine.]
[L01BC08, decitabine, Decitabine may increase the immunosuppressive activities of Cyclosporine.]
[A11HA08, tocophersolan, The metabolism of Tocofersolan can be decreased when combined with Cyclosporine.]
[L04AX05, pirfenidone, Pirfenidone may increase the immunosuppressive activities of Cyclosporine.]
[L01EX09, nintedanib, The metabolism of Cyclosporine can be decreased when combined with Nintedanib.]
[S03AA06, gentamicin, Cyclosporine may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[L01FX07, blinatumomab, Blinatumomab may increase the immunosuppressive activities of Cyclosporine.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Cyclosporine.]
[L01XK01, olaparib, Olaparib may increase the immunosuppressive activities of Cyclosporine.]
[B01AF03, edoxaban, The serum concentration of Edoxaban can be increased when it is combined with Cyclosporine.]
[N06AX11, mirtazapine, The metabolism of Mirtazapine can be decreased when combined with Cyclosporine.]
[L04AC10, secukinumab, Secukinumab may increase the immunosuppressive activities of Cyclosporine.]
[L01EF01, palbociclib, Palbociclib may increase the immunosuppressive activities of Cyclosporine.]
[L01EX08, lenvatinib, Cyclosporine may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L01XH03, panobinostat, Panobinostat may increase the immunosuppressive activities of Cyclosporine.]
[J05AP07, daclatasvir, The serum concentration of Cyclosporine can be increased when it is combined with Daclatasvir.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Cyclosporine.]
[L01DC01, bleomycin, Bleomycin may increase the immunosuppressive activities of Cyclosporine.]
[C01EB17, ivabradine, The metabolism of Ivabradine can be decreased when combined with Cyclosporine.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Adefovir dipivoxil.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Cyclosporine.]
[A07DA06, eluxadoline, The serum concentration of Eluxadoline can be increased when it is combined with Cyclosporine.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Cyclosporine.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Cyclosporine.]
[A04AD14, rolapitant, The serum concentration of Cyclosporine can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The metabolism of Flibanserin can be decreased when combined with Cyclosporine.]
[N05AX15, cariprazine, The metabolism of Cariprazine can be decreased when combined with Cyclosporine.]
[M02AA25, aceclofenac, The risk or severity of renal failure and hypertension can be increased when Aceclofenac is combined with Cyclosporine.]
[M01AB11, acemetacin, The risk or severity of renal failure and hypertension can be increased when Acemetacin is combined with Cyclosporine.]
[S01EC01, acetazolamide, The serum concentration of Cyclosporine can be increased when it is combined with Acetazolamide.]
[N05AB07, acetophenazine, Cyclosporine may increase the neurotoxic activities of Acetophenazine.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Acipimox.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Cyclosporine.]
[V03AB37, idarucizumab, Cyclosporine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, Trabectedin may increase the immunosuppressive activities of Cyclosporine.]
[R03DX09, mepolizumab, Mepolizumab may increase the immunosuppressive activities of Cyclosporine.]
[J02AC05, isavuconazole, The serum concentration of Cyclosporine can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Cyclosporine.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cyclosporine.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Cyclosporine.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Cyclosporine.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Cyclosporine.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Cyclosporine.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Cyclosporine.]
[M04AB05, lesinurad, The metabolism of Cyclosporine can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The metabolism of Cyclosporine can be decreased when combined with Elbasvir.]
[J05AP11, grazoprevir, The metabolism of Grazoprevir can be decreased when combined with Cyclosporine.]
[N05CA05, aprobarbital, The metabolism of Cyclosporine can be increased when combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of renal failure and hypertension can be increased when Alminoprofen is combined with Cyclosporine.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Cyclosporine.]
[L04AC13, ixekizumab, Ixekizumab may increase the immunosuppressive activities of Cyclosporine.]
[L01XX52, venetoclax, The serum concentration of Venetoclax can be increased when it is combined with Cyclosporine.]
[N05BA08, bromazepam, Cyclosporine may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The serum concentration of Cyclosporine can be increased when it is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium Aluminum Silicate.]
[D07AC11, amcinonide, The risk or severity of adverse effects can be increased when Amcinonide is combined with Cyclosporine.]
[N06AA19, amineptin, The risk or severity of hypertension can be increased when Cyclosporine is combined with Amineptine.]
[C08CA01, amlodipine, The metabolism of Amlodipine can be decreased when combined with Cyclosporine.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Cyclosporine.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Cyclosporine is combined with Obeticholic acid.]
[C03CA02, bumetanide, The risk or severity of renal failure can be increased when Bumetanide is combined with Cyclosporine.]
[N01BB01, bupivacaine, The metabolism of Bupivacaine can be decreased when combined with Cyclosporine.]
[C07AA19, bupranolol, The metabolism of Bupranolol can be decreased when combined with Cyclosporine.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Cyclosporine.]
[N05BE01, buspirone, The metabolism of Buspirone can be decreased when combined with Cyclosporine.]
[L01AB01, busulfan, Busulfan may increase the immunosuppressive activities of Cyclosporine.]
[L01XX27, arsenic trioxide, Arsenic trioxide may increase the immunosuppressive activities of Cyclosporine.]
[P01BE02, artemether, The metabolism of Cyclosporine can be decreased when combined with Artemether.]
[M02AA03, clofezone, Cyclosporine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[J01MA09, sparfloxacin, The risk or severity of nephrotoxicity can be increased when Sparfloxacin is combined with Cyclosporine.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Cyclosporine.]
[L01XK03, rucaparib, The metabolism of Cyclosporine can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Cyclosporine can be decreased when combined with Azithromycin.]
[L04AC12, brodalumab, Brodalumab may increase the immunosuppressive activities of Cyclosporine.]
[L01EF02, ribociclib, The metabolism of Cyclosporine can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of renal failure and hypertension can be increased when Balsalazide is combined with Cyclosporine.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Bambuterol.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Cyclosporine.]
[A06AH05, naldemedine, Cyclosporine may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Cyclosporine.]
[N02BF02, pregabalin, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Cyclosporine.]
[N03AX30, beclamide, The therapeutic efficacy of Beclamide can be decreased when used in combination with Cyclosporine.]
[C09AA07, benazepril, Cyclosporine may decrease the antihypertensive activities of Benazepril.]
[D05AX03, calcitriol, The metabolism of Cyclosporine can be increased when combined with Calcitriol.]
[P01CA02, benznidazole, Cyclosporine may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[L04AC01, daclizumab, Daclizumab may increase the immunosuppressive activities of Cyclosporine.]
[J01XX08, linezolid, Linezolid may increase the immunosuppressive activities of Cyclosporine.]
[J05AF06, abacavir, Cyclosporine may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Cyclosporine can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Cyclosporine.]
[L04AB02, infliximab, Infliximab may increase the immunosuppressive activities of Cyclosporine.]
[L01EX10, midostaurin, The metabolism of Cyclosporine can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Cyclosporine.]
[N04BD03, safinamide, The metabolism of Safinamide can be decreased when combined with Cyclosporine.]
[L04AC14, sarilumab, Sarilumab may increase the immunosuppressive activities of Cyclosporine.]
[J01MA23, delafloxacin, The risk or severity of nephrotoxicity can be increased when Delafloxacin is combined with Cyclosporine.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Cyclosporine.]
[L04AC16, guselkumab, Guselkumab may increase the immunosuppressive activities of Cyclosporine.]
[D01AC10, bifonazole, The metabolism of Cyclosporine can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, Capecitabine may increase the immunosuppressive activities of Cyclosporine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Cyclosporine.]
[L01EH02, neratinib, The serum concentration of Cyclosporine can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Cyclosporine.]
[L01XH01, vorinostat, Vorinostat may increase the immunosuppressive activities of Cyclosporine.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Cyclosporine.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Cyclosporine.]
[A02BX12, bismuth subnitrate, Cyclosporine may increase the neurotoxic activities of Bismuth subnitrate.]
[C07AB07, bisoprolol, The metabolism of Bisoprolol can be decreased when combined with Cyclosporine.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Bitolterol.]
[J05AG03, efavirenz, The serum concentration of Cyclosporine can be decreased when it is combined with Efavirenz.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefprozil.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Cyclosporine.]
[L04AC02, basiliximab, Basiliximab may increase the immunosuppressive activities of Cyclosporine.]
[L01BA03, raltitrexed, Raltitrexed may increase the immunosuppressive activities of Cyclosporine.]
[N05AD06, bromperidol, Cyclosporine may increase the neurotoxic activities of Bromperidol.]
[N05CD09, brotizolam, The metabolism of Brotizolam can be decreased when combined with Cyclosporine.]
[C03DA03, canrenone, The risk or severity of hyperkalemia can be increased when Canrenone is combined with Cyclosporine.]
[R03BA02, budesonide, Budesonide may increase the immunosuppressive activities of Cyclosporine.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Cyclosporine is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of renal failure and hypertension can be increased when Bumadizone is combined with Cyclosporine.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Cyclosporine.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Cyclosporine.]
[N06AA15, butriptyline, The risk or severity of hypertension can be increased when Cyclosporine is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The serum concentration of Acetyldigoxin can be increased when it is combined with Cyclosporine.]
[N01BX04, capsaicin, The metabolism of Cyclosporine can be decreased when combined with Capsaicin.]
[A10BK04, ertugliflozin, Cyclosporine may decrease the excretion rate of Ertugliflozin which could result in a higher serum level.]
[R06AX18, acrivastine, Cyclosporine may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Captopril.]
[V04CD06, macimorelin, The metabolism of Macimorelin can be decreased when combined with Cyclosporine.]
[L02BB05, apalutamide, The serum concentration of Cyclosporine can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Cyclosporine can be decreased when it is combined with Carbamazepine.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Carbimazole.]
[L03AB06, interferon alfa-n1, Interferon alfa-n1 may increase the immunosuppressive activities of Cyclosporine.]
[C07AG02, carvedilol, The serum concentration of Cyclosporine can be increased when it is combined with Carvedilol.]
[B02BX09, fostamatinib, The metabolism of Cyclosporine can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Cyclosporine can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Cyclosporine.]
[L04AA37, baricitinib, Baricitinib may increase the immunosuppressive activities of Cyclosporine.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefepime.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefetamet.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefodizime.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceforanide.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefpodoxime.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Cyclosporine.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Cyclosporine.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftibuten.]
[J01GB14, plazomicin, Cyclosporine may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The metabolism of Celiprolol can be decreased when combined with Cyclosporine.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Cyclosporine.]
[L01XX62, ivosidenib, The metabolism of Ivosidenib can be decreased when combined with Cyclosporine.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Cyclosporine.]
[A16AX14, migalastat, Cyclosporine may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Cyclosporine can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, Cyclosporine may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.]
[J05AX24, tecovirimat, The metabolism of Cyclosporine can be increased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Cyclosporine can be decreased when combined with Doravirine.]
[J01AA13, eravacycline, The metabolism of Eravacycline can be decreased when combined with Cyclosporine.]
[L01EM04, duvelisib, The metabolism of Cyclosporine can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Cyclosporine.]
[J01AA14, sarecycline, The serum concentration of Cyclosporine can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Cyclosporine.]
[S01GX12, cetirizine, Cyclosporine may decrease the excretion rate of Cetirizine which could result in a higher serum level.]
[D08AE05, chloroxylenol, Cyclosporine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of renal failure and hypertension can be increased when Lornoxicam is combined with Cyclosporine.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Inotersen.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Cyclosporine.]
[R03BB08, revefenacin, Cyclosporine may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L01ED05, lorlatinib, The serum concentration of Cyclosporine can be decreased when it is combined with Lorlatinib.]
[L04AA39, emapalumab, Emapalumab may increase the immunosuppressive activities of Cyclosporine.]
[L01AD01, carmustine, Carmustine may increase the immunosuppressive activities of Cyclosporine.]
[L01EX12, larotrectinib, The metabolism of Larotrectinib can be decreased when combined with Cyclosporine.]
[L01EX13, gilteritinib, The metabolism of Cyclosporine can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The serum concentration of Cyclosporine can be increased when it is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of seizure can be increased when Cyclosporine is combined with Amifampridine.]
[L04AA43, ravulizumab, Ravulizumab may increase the immunosuppressive activities of Cyclosporine.]
[A06AX05, prucalopride, The serum concentration of Prucalopride can be increased when it is combined with Cyclosporine.]
[C09AA08, cilazapril, Cyclosporine may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Cyclosporine.]
[A03FA08, cinitapride, The risk or severity of hypertension can be increased when Cyclosporine is combined with Cinitapride.]
[C10AB08, ciprofibrate, The risk or severity of renal failure can be increased when Cyclosporine is combined with Ciprofibrate.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Cyclosporine.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Cyclosporine.]
[L04AA42, siponimod, Siponimod may increase the immunosuppressive activities of Cyclosporine.]
[J01FA09, clarithromycin, The metabolism of Cyclosporine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Cyclosporine.]
[N06AX29, brexanolone, The therapeutic efficacy of Brexanolone can be decreased when used in combination with Cyclosporine.]
[L01EN01, erdafitinib, The serum concentration of Cyclosporine can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The metabolism of Cyclosporine can be increased when combined with Clobazam.]
[D07AB21, clocortolone, The risk or severity of adverse effects can be increased when Clocortolone is combined with Cyclosporine.]
[J01AA11, clomocycline, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Clomocycline.]
[H02AB14, cloprednol, Cloprednol may increase the immunosuppressive activities of Cyclosporine.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Ubidecarenone.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Candesartan is combined with Cyclosporine.]
[L04AB01, etanercept, Etanercept may increase the immunosuppressive activities of Cyclosporine.]
[V03AE02, sevelamer, The serum concentration of Cyclosporine can be decreased when it is combined with Sevelamer.]
[H02AB17, cortivazol, Cortivazol may increase the immunosuppressive activities of Cyclosporine.]
[L04AC18, risankizumab, Risankizumab may increase the immunosuppressive activities of Cyclosporine.]
[L01EM03, alpelisib, The serum concentration of Alpelisib can be increased when it is combined with Cyclosporine.]
[L01FX14, polatuzumab vedotin, The metabolism of Polatuzumab vedotin can be decreased when combined with Cyclosporine.]
[J01DC04, cefaclor, Cyclosporine may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefadroxil.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefamandole.]
[L01XX66, selinexor, The metabolism of Selinexor can be decreased when combined with Cyclosporine.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefatrizine.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefazolin.]
[L02BB06, darolutamide, The metabolism of Darolutamide can be decreased when combined with Cyclosporine.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefmetazole.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefonicid.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Cyclosporine.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefoperazone.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefotaxime.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefotetan.]
[N05AA06, cyamemazine, Cyclosporine may increase the neurotoxic activities of Cyamemazine.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefotiam.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefoxitin.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefsulodin.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftazidime.]
[C03BX03, cicletanine, Cyclosporine may decrease the antihypertensive activities of Cicletanine.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftizoxime.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftriaxone.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefuroxime.]
[M03BX08, cyclobenzaprine, The metabolism of Cyclobenzaprine can be decreased when combined with Cyclosporine.]
[L04AA44, upadacitinib, Upadacitinib may increase the immunosuppressive activities of Cyclosporine.]
[L01EJ02, fedratinib, The serum concentration of Cyclosporine can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Cyclosporine.]
[N07XX11, pitolisant, The serum concentration of Cyclosporine can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The serum concentration of Pretomanid can be increased when it is combined with Cyclosporine.]
[J01XX12, lefamulin, Cyclosporine may decrease the excretion rate of Lefamulin which could result in a higher serum level.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Cyclosporine.]
[C03AA09, cyclothiazide, The risk or severity of renal failure can be increased when Cyclothiazide is combined with Cyclosporine.]
[G04BE04, yohimbine, The metabolism of Yohimbine can be decreased when combined with Cyclosporine.]
[J01XX09, daptomycin, The serum concentration of Daptomycin can be increased when it is combined with Cyclosporine.]
[J01DB01, cephalexin, The metabolism of Cyclosporine can be decreased when combined with Cephalexin.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefaloridine.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefalotin.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefapirin.]
[J01DB09, cephradine, The metabolism of Cyclosporine can be increased when combined with Cefradine.]
[H02AB13, deflazacort, Deflazacort may increase the immunosuppressive activities of Cyclosporine.]
[G03DB05, demegestone, The metabolism of Cyclosporine can be decreased when combined with Demegestone.]
[L01FD01, trastuzumab, Trastuzumab may increase the immunosuppressive activities of Cyclosporine.]
[L01FD03, ado-trastuzumab emtansine, Trastuzumab emtansine may increase the immunosuppressive activities of Cyclosporine.]
[N02CC08, lasmiditan, The serum concentration of Cyclosporine can be increased when it is combined with Lasmiditan.]
[L04AX09, diroximel fumarate, Diroximel fumarate may increase the immunosuppressive activities of Cyclosporine.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Cyclosporine.]
[G03AC09, desogestrel, The metabolism of Cyclosporine can be decreased when combined with Desogestrel.]
[B06AX03, voxelotor, The serum concentration of Cyclosporine can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Cyclosporine can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Givosiran.]
[M09AX08, golodirsen, Cyclosporine may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Cyclosporine.]
[L01FX13, enfortumab vedotin, The metabolism of Enfortumab vedotin can be decreased when combined with Cyclosporine.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be decreased when combined with Cyclosporine.]
[S01XA12, dexpanthenol, Cyclosporine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Cyclosporine.]
[N05CM21, lemborexant, The metabolism of Cyclosporine can be decreased when combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Cyclosporine can be decreased when combined with Tazemetostat.]
[L04AA53, teprotumumab, Teprotumumab may increase the immunosuppressive activities of Cyclosporine.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be increased when it is combined with Cyclosporine.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Cyclosporine.]
[C10AX15, bempedoic acid, The excretion of Bempedoic acid can be decreased when combined with Cyclosporine.]
[J05AB16, remdesivir, The metabolism of Cyclosporine can be decreased when combined with Remdesivir.]
[S01AE06, gatifloxacin, The risk or severity of nephrotoxicity can be increased when Gatifloxacin is combined with Cyclosporine.]
[H02CA02, osilodrostat, The metabolism of Cyclosporine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Cyclosporine can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of hypertension can be increased when Cyclosporine is combined with Frovatriptan.]
[G04CB02, dutasteride, The metabolism of Cyclosporine can be decreased when combined with Dutasteride.]
[L04AA38, ozanimod, Ozanimod may increase the immunosuppressive activities of Cyclosporine.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Cyclosporine.]
[R02AA03, dichlorobenzyl alcohol, Cyclosporine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The metabolism of Cyclosporine can be decreased when combined with Dienogest.]
[D07AC19, difluprednate, The risk or severity of adverse effects can be increased when Difluprednate is combined with Cyclosporine.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be decreased when combined with Cyclosporine.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Cyclosporine.]
[M01AH02, rofecoxib, The risk or severity of renal failure and hypertension can be increased when Rofecoxib is combined with Cyclosporine.]
[L01XF03, bexarotene, Bexarotene may increase the immunosuppressive activities of Cyclosporine.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be decreased when combined with Cyclosporine.]
[C01BD07, dronedarone, The serum concentration of Dronedarone can be increased when it is combined with Cyclosporine.]
[N03AG02, dipropylacetamide, The therapeutic efficacy of Valpromide can be decreased when used in combination with Cyclosporine.]
[J01FA13, dirithromycin, The metabolism of Cyclosporine can be decreased when combined with Dirithromycin.]
[L01AA02, chlorambucil, Chlorambucil may increase the immunosuppressive activities of Cyclosporine.]
[S03AA08, chloramphenicol, The serum concentration of Cyclosporine can be increased when it is combined with Chloramphenicol.]
[C02AA06, methoserpidine, Cyclosporine may decrease the antihypertensive activities of Methoserpidine.]
[L01EN02, pemigatinib, The metabolism of Pemigatinib can be decreased when combined with Cyclosporine.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Cyclosporine which could result in a higher serum level.]
[L01EX17, capmatinib, The serum concentration of Cyclosporine can be increased when it is combined with Capmatinib.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Dopexamine.]
[D07XB03, fluprednidene, Fluprednidene may increase the immunosuppressive activities of Cyclosporine.]
[M01AC04, droxicam, The risk or severity of renal failure and hypertension can be increased when Droxicam is combined with Cyclosporine.]
[L01EX19, ripretinib, The serum concentration of Cyclosporine can be increased when it is combined with Ripretinib.]
[V08CA05, mangafodipir, Cyclosporine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The metabolism of Selpercatinib can be decreased when combined with Cyclosporine.]
[S01BA14, loteprednol, The risk or severity of adverse effects can be increased when Loteprednol is combined with Cyclosporine.]
[M02AA27, dexketoprofen, The risk or severity of renal failure and hypertension can be increased when Dexketoprofen is combined with Cyclosporine.]
[N05CM02, chlormethiazole, The metabolism of Clomethiazole can be decreased when combined with Cyclosporine.]
[L04AA47, inebilizumab, Inebilizumab may increase the immunosuppressive activities of Cyclosporine.]
[L01XX69, lurbinectedin, The serum concentration of Lurbinectedin can be increased when it is combined with Cyclosporine.]
[R05CB11, stepronin, Stepronin may increase the immunosuppressive activities of Cyclosporine.]
[C08CA17, levamlodipine, The serum concentration of Cyclosporine can be increased when it is combined with Levamlodipine.]
[R06AX22, ebastine, The metabolism of Cyclosporine can be decreased when combined with Ebastine.]
[J05AX29, fostemsavir, The metabolism of Fostemsavir can be decreased when combined with Cyclosporine.]
[L01FX15, belantamab mafodotin, Cyclosporine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L04AC19, satralizumab, Satralizumab may increase the immunosuppressive activities of Cyclosporine.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be increased when it is combined with Cyclosporine.]
[P01BA01, chloroquine, The serum concentration of Cyclosporine can be increased when it is combined with Chloroquine.]
[L01EX23, pralsetinib, The serum concentration of Pralsetinib can be increased when it is combined with Cyclosporine.]
[C03AA04, chlorothiazide, The risk or severity of renal failure can be increased when Chlorothiazide is combined with Cyclosporine.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be decreased when combined with Cyclosporine.]
[N05AA01, chlorpromazine, The metabolism of Chlorpromazine can be decreased when combined with Cyclosporine.]
[A10BB02, chlorpropamide, Cyclosporine may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.]
[N05AF03, chlorprothixene, Cyclosporine may increase the neurotoxic activities of Chlorprothixene.]
[C03BA04, chlorthalidone, The risk or severity of renal failure can be increased when Chlorthalidone is combined with Cyclosporine.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Cyclosporine.]
[A11CC05, cholecalciferol, The metabolism of Cholecalciferol can be decreased when combined with Cyclosporine.]
[V04CK02, cholecystokinin, The excretion of Cholecystokinin can be decreased when combined with Cyclosporine.]
[N02BA07, ethenzamide, The risk or severity of renal failure and hypertension can be increased when Ethenzamide is combined with Cyclosporine.]
[N02BA03, choline salicylate, Cyclosporine may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The metabolism of Vinpocetine can be decreased when combined with Cyclosporine.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be decreased when combined with Cyclosporine.]
[M01AB08, etodolac, The risk or severity of renal failure and hypertension can be increased when Etodolac is combined with Cyclosporine.]
[M02AA06, etofenamate, The risk or severity of renal failure and hypertension can be increased when Etofenamate is combined with Cyclosporine.]
[C10AB09, etofibrate, The risk or severity of renal failure can be increased when Cyclosporine is combined with Etofibrate.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Cyclosporine.]
[A16AX20, lonafarnib, The metabolism of Cyclosporine can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, Fludarabine may increase the immunosuppressive activities of Cyclosporine.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Cyclosporine.]
[M01AX25, chondroitin sulfates, Cyclosporine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Cyclosporine is combined with Naxitamab.]
[L04AD03, voclosporin, Voclosporin may increase the immunosuppressive activities of Cyclosporine.]
[P03AX07, abametapir, The serum concentration of Cyclosporine can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Tepotinib can be increased when it is combined with Cyclosporine.]
[L01EX25, umbralisib, The serum concentration of Cyclosporine can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, Cyclosporine may decrease the excretion rate of Trilaciclib which could result in a higher serum level.]
[N03AX10, felbamate, The metabolism of Cyclosporine can be increased when combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of renal failure and hypertension can be increased when Fenbufen is combined with Cyclosporine.]
[C01CA19, fenoldopam, Cyclosporine may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Cyclosporine is combined with Fenozolone.]
[G04CB01, finasteride, The metabolism of Cyclosporine can be decreased when combined with Finasteride.]
[J01DD15, cefdinir, Cyclosporine may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of nephrotoxicity can be increased when Flumequine is combined with Cyclosporine.]
[R03BA03, flunisolide, Flunisolide may increase the immunosuppressive activities of Cyclosporine.]
[S01JA01, fluorescein, Cyclosporine may decrease the excretion rate of Fluorescein which could result in a higher serum level.]
[N02BG07, flupirtine, Cyclosporine may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Cyclosporine.]
[L04AA50, ponesimod, Ponesimod may increase the immunosuppressive activities of Cyclosporine.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Cyclosporine.]
[N01AB05, trichloroethylene, The risk or severity of hypertension can be increased when Cyclosporine is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, Peginterferon alfa-2b may increase the immunosuppressive activities of Cyclosporine.]
[H04AA02, dasiglucagon, Cyclosporine may decrease the antihypertensive activities of Dasiglucagon.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Cyclosporine.]
[A02BA01, cimetidine, The metabolism of Cyclosporine can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Cyclosporine.]
[V08CA04, gadoteridol, Cyclosporine may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Cyclosporine.]
[J01MB06, cinoxacin, The risk or severity of nephrotoxicity can be increased when Cinoxacin is combined with Cyclosporine.]
[L01XX73, sotorasib, The serum concentration of Cyclosporine can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Cyclosporine.]
[S03AA07, ciprofloxacin, Cyclosporine may increase the nephrotoxic activities of Ciprofloxacin.]
[L01XA01, cisplatin, Cisplatin may increase the immunosuppressive activities of Cyclosporine.]
[N06AB04, citalopram, The metabolism of Citalopram can be decreased when combined with Cyclosporine.]
[L04AA54, pegcetacoplan, Pegcetacoplan may increase the immunosuppressive activities of Cyclosporine.]
[J02AX07, ibrexafungerp, The metabolism of Ibrexafungerp can be decreased when combined with Cyclosporine.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Cyclosporine.]
[L04AA48, belumosudil, Belumosudil may increase the immunosuppressive activities of Cyclosporine.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Cyclosporine.]
[L04AA51, anifrolumab, Anifrolumab may increase the immunosuppressive activities of Cyclosporine.]
[L01XX74, belzutifan, The serum concentration of Cyclosporine can be decreased when it is combined with Belzutifan.]
[L01EB10, mobocertinib, The serum concentration of Cyclosporine can be decreased when it is combined with Mobocertinib.]
[L01FX23, tisotumab vedotin, The metabolism of Tisotumab vedotin can be decreased when combined with Cyclosporine.]
[N02CD07, atogepant, The serum concentration of Atogepant can be increased when it is combined with Cyclosporine.]
[V09AB03, ioflupane I-123, Cyclosporine may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Cyclosporine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Cyclosporine.]
[V09AX06, florbetaben f-18, Cyclosporine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[L04AA59, avacopan, The metabolism of Cyclosporine can be decreased when combined with Avacopan.]
[A10BB12, glimepiride, Cyclosporine may decrease the excretion rate of Glimepiride which could result in a higher serum level.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Clenbuterol.]
[J01FF01, clindamycin, The metabolism of Cyclosporine can be decreased when combined with Clindamycin.]
[N06AX25, St. John's wort extract, The serum concentration of Cyclosporine can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Cyclosporine can be increased when it is combined with Asciminib.]
[L02BG06, exemestane, The metabolism of Exemestane can be decreased when combined with Cyclosporine.]
[J05AX10, maribavir, The serum concentration of Cyclosporine can be increased when it is combined with Maribavir.]
[L03AB15, ropeginterferon alfa-2b, Ropeginterferon alfa-2b may increase the immunosuppressive activities of Cyclosporine.]
[D07AD01, clobetasol, The risk or severity of adverse effects can be increased when Clobetasol is combined with Cyclosporine.]
[D11AH08, abrocitinib, The serum concentration of Cyclosporine can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Cyclosporine can be increased when it is combined with Clofazimine.]
[C10AB01, clofibrate, The risk or severity of renal failure can be increased when Cyclosporine is combined with Clofibrate.]
[B06AX04, mitapivat, The risk or severity of renal failure can be increased when Mitapivat is combined with Cyclosporine.]
[N01BB10, levobupivacaine, Cyclosporine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01EJ03, pacritinib, The serum concentration of Pacritinib can be increased when it is combined with Cyclosporine.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Cyclosporine.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Cyclosporine.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be decreased when combined with Cyclosporine.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Cyclosporine.]
[J05AB17, brincidofovir, The serum concentration of Brincidofovir can be increased when it is combined with Cyclosporine.]
[C01EB24, mavacamten, The serum concentration of Mavacamten can be increased when it is combined with Cyclosporine.]
[J05AH02, oseltamivir, Cyclosporine may decrease the excretion rate of Oseltamivir which could result in a higher serum level.]
[C03BA03, clopamide, The risk or severity of renal failure can be increased when Clopamide is combined with Cyclosporine.]
[A02BC08, vonoprazan, The metabolism of Cyclosporine can be decreased when combined with Vonoprazan.]
[L04AC22, spesolimab, Spesolimab may increase the immunosuppressive activities of Cyclosporine.]
[L04AA56, deucravacitinib, Deucravacitinib may increase the immunosuppressive activities of Cyclosporine.]
[A05BA08, glycyrrhizic acid, Cyclosporine may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[N05AH06, clothiapine, Cyclosporine may increase the neurotoxic activities of Clothiapine.]
[N05BA21, clotiazepam, The metabolism of Clotiazepam can be decreased when combined with Cyclosporine.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Cyclosporine.]
[A04AA02, granisetron, The metabolism of Granisetron can be decreased when combined with Cyclosporine.]
[J05AX31, lenacapavir, The metabolism of Cyclosporine can be decreased when combined with Lenacapavir.]
[N05AH02, clozapine, The metabolism of Clozapine can be decreased when combined with Cyclosporine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Cyclosporine.]
[A10BK06, sotagliflozin, The serum concentration of Cyclosporine can be increased when it is combined with Sotagliflozin.]
[J01GB12, arbekacin, Cyclosporine may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[D07AC12, halometasone, The risk or severity of adverse effects can be increased when Halometasone is combined with Cyclosporine.]
[H01AC08, somatrogon, The metabolism of Cyclosporine can be increased when combined with Somatrogon.]
[M09AX11, palovarotene, The metabolism of Palovarotene can be decreased when combined with Cyclosporine.]
[C02KB01, metyrosine, Cyclosporine may decrease the antihypertensive activities of Metyrosine.]
[L04AC21, bimekizumab, Bimekizumab may increase the immunosuppressive activities of Cyclosporine.]
[M01AX13, proquazone, The risk or severity of renal failure and hypertension can be increased when Proquazone is combined with Cyclosporine.]
[R05DA04, codeine, The metabolism of Codeine can be decreased when combined with Cyclosporine.]
[M04AC01, colchicine, The serum concentration of Colchicine can be increased when it is combined with Cyclosporine.]
[J01XB01, colistin, Cyclosporine may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefpirome.]
[L04AA13, leflunomide, Leflunomide may increase the immunosuppressive activities of Cyclosporine.]
[N01AB07, desflurane, The risk or severity of hypertension can be increased when Cyclosporine is combined with Desflurane.]
[A04AA03, tropisetron, Cyclosporine may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[C04AX28, ifenprodil, The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Cyclosporine.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Cyclosporine.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of renal failure and hypertension can be increased when Imidazole salicylate is combined with Cyclosporine.]
[L01BB07, nelarabine, Nelarabine may increase the immunosuppressive activities of Cyclosporine.]
[J01FA15, telithromycin, The metabolism of Cyclosporine can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, Ciclesonide may increase the immunosuppressive activities of Cyclosporine.]
[B01AC10, indobufen, The risk or severity of renal failure and hypertension can be increased when Indobufen is combined with Cyclosporine.]
[J05AB14, valganciclovir, Cyclosporine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Cyclosporine may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Cyclosporine may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Cyclosporine may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Cyclosporine may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Cyclosporine may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of renal failure and hypertension can be increased when Valdecoxib is combined with Cyclosporine.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Cyclosporine is combined with Isometheptene.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Cyclosporine.]
[M01AH04, parecoxib, The risk or severity of renal failure and hypertension can be increased when Parecoxib is combined with Cyclosporine.]
[J02AC02, itraconazole, The metabolism of Cyclosporine can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Bemiparin.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Acyclovir.]
[N05BA10, ketazolam, The metabolism of Cyclosporine can be decreased when combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of renal failure and hypertension can be increased when Kebuzone is combined with Cyclosporine.]
[L01EA01, imatinib, The serum concentration of Cyclosporine can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Cyclosporine can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The serum concentration of Cyclosporine can be increased when it is combined with Esomeprazole.]
[C08CA09, lacidipine, The metabolism of Lacidipine can be decreased when combined with Cyclosporine.]
[N03AX09, lamotrigine, The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Cyclosporine.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Nafarelin.]
[S01BA03, cortisone, The risk or severity of adverse effects can be increased when Cortisone is combined with Cyclosporine.]
[N07BC04, lofexidine, The metabolism of Lofexidine can be decreased when combined with Cyclosporine.]
[S01AE04, lomefloxacin, The risk or severity of nephrotoxicity can be increased when Lomefloxacin is combined with Cyclosporine.]
[M01AB09, lonazolac, The risk or severity of renal failure and hypertension can be increased when Lonazolac is combined with Cyclosporine.]
[R06AX13, loratadine, Cyclosporine may decrease the excretion rate of Loratadine which could result in a higher serum level.]
[M02AA31, loxoprofen, The risk or severity of renal failure and hypertension can be increased when Loxoprofen is combined with Cyclosporine.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Loracarbef.]
[C09AA03, lisinopril, Cyclosporine may decrease the antihypertensive activities of Lisinopril.]
[A06AD01, magnesium carbonate, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium carbonate.]
[B05XA10, magnesium phosphate, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium phosphate.]
[C08CA11, manidipine, The metabolism of Cyclosporine can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Mebeverine.]
[S01BA08, medrysone, The risk or severity of adverse effects can be increased when Medrysone is combined with Cyclosporine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Cyclosporine is combined with Mefenorex.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Cyclosporine.]
[H02AB15, meprednisone, Meprednisone may increase the immunosuppressive activities of Cyclosporine.]
[R06AD07, mequitazine, The metabolism of Mequitazine can be decreased when combined with Cyclosporine.]
[J01DH02, meropenem, Cyclosporine may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C04AX01, cyclandelate, The metabolism of Cyclandelate can be decreased when combined with Cyclosporine.]
[R03CB02, methoxyphenamine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Methoxyphenamine.]
[C03DA04, eplerenone, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Cyclosporine.]
[N05AD03, metylperon, Cyclosporine may decrease the excretion rate of Melperone which could result in a higher serum level.]
[L04AA15, alefacept, Alefacept may increase the immunosuppressive activities of Cyclosporine.]
[C03AA07, cyclopenthiazide, The risk or severity of renal failure can be increased when Cyclopenthiazide is combined with Cyclosporine.]
[J01FA03, midecamycin, The metabolism of Cyclosporine can be decreased when combined with Midecamycin.]
[J05AF07, tenofovir disoproxil, Cyclosporine may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, The serum concentration of Cyclosporine can be decreased when it is combined with Cyclophosphamide.]
[N06AX07, minaprine, The metabolism of Minaprine can be decreased when combined with Cyclosporine.]
[J04AB01, cycloserine, Cyclosporine may increase the neurotoxic activities of Cycloserine.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, Antilymphocyte immunoglobulin (horse) may increase the immunosuppressive activities of Cyclosporine.]
[S01AA13, fusidic acid, The metabolism of Fusidic acid can be decreased when combined with Cyclosporine.]
[J01MB04, pipemidic acid, The risk or severity of nephrotoxicity can be increased when Pipemidic acid is combined with Cyclosporine.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may increase the immunosuppressive activities of Cyclosporine.]
[M01AG01, mefenamic acid, The risk or severity of renal failure and hypertension can be increased when Mefenamic acid is combined with Cyclosporine.]
[N06AG02, moclobemide, The metabolism of Moclobemide can be decreased when combined with Cyclosporine.]
[N06BA07, modafinil, The serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil.]
[C09AA13, moexipril, Cyclosporine may decrease the antihypertensive activities of Moexipril.]
[C10AA07, rosuvastatin, The serum concentration of Rosuvastatin can be increased when it is combined with Cyclosporine.]
[M02AA02, mofebutazone, The risk or severity of renal failure and hypertension can be increased when Mofebutazone is combined with Cyclosporine.]
[M01AX22, morniflumate, The risk or severity of renal failure and hypertension can be increased when Morniflumate is combined with Cyclosporine.]
[C03XA02, conivaptan, The metabolism of Cyclosporine can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, Cyclosporine may decrease the antihypertensive activities of Moxonidine.]
[L01BC01, cytarabine, Cytarabine may increase the immunosuppressive activities of Cyclosporine.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Cyclosporine.]
[M01AH05, etoricoxib, The risk or severity of renal failure and hypertension can be increased when Etoricoxib is combined with Cyclosporine.]
[L01AX04, dacarbazine, Dacarbazine may increase the immunosuppressive activities of Cyclosporine.]
[L01DA01, dactinomycin, Dactinomycin may increase the immunosuppressive activities of Cyclosporine.]
[G03XA01, danazol, The risk or severity of liver damage can be increased when Danazol is combined with Cyclosporine.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Dantrolene.]
[J04BA02, dapsone, The metabolism of Cyclosporine can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, Daunorubicin may increase the immunosuppressive activities of Cyclosporine.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Cyclosporine.]
[A04AD11, nabilone, The metabolism of Nabilone can be decreased when combined with Cyclosporine.]
[M01AX01, nabumetone, The risk or severity of renal failure and hypertension can be increased when Nabumetone is combined with Cyclosporine.]
[N07BB05, nalmefene, Cyclosporine may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Cyclosporine.]
[J01AA01, demeclocycline, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Demeclocycline.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Cyclosporine.]
[S01GX04, nedocromil, Cyclosporine may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Cyclosporine can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Cyclosporine may decrease the antihypertensive activities of Nicorandil.]
[L02BB02, nilutamide, Cyclosporine may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[N03AG06, tiagabine, The metabolism of Tiagabine can be decreased when combined with Cyclosporine.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be decreased when combined with Cyclosporine.]
[C01CA23, theodrenaline, The risk or severity of hypertension can be increased when Cyclosporine is combined with Theodrenaline.]
[M03AC11, cisatracurium, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Cyclosporine.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Norfenefrine.]
[B01AX05, fondaparinux, Cyclosporine may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclosporine.]
[N06AB10, escitalopram, The metabolism of Escitalopram can be decreased when combined with Cyclosporine.]
[G04BD08, solifenacin, The metabolism of Solifenacin can be decreased when combined with Cyclosporine.]
[A07EC03, olsalazine, The risk or severity of renal failure and hypertension can be increased when Olsalazine is combined with Cyclosporine.]
[N06AA01, desipramine, The metabolism of Desipramine can be decreased when combined with Cyclosporine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Cyclosporine.]
[S01BA11, desonide, The risk or severity of adverse effects can be increased when Desonide is combined with Cyclosporine.]
[D07XC02, desoximetasone, Desoximetasone may increase the immunosuppressive activities of Cyclosporine.]
[H02AA03, desoxycorticosterone, The risk or severity of adverse effects can be increased when Desoxycortone is combined with Cyclosporine.]
[J01DH03, ertapenem, Cyclosporine may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[C09XA02, aliskiren, The serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.]
[L01XA03, oxaliplatin, Oxaliplatin may increase the immunosuppressive activities of Cyclosporine.]
[M01AE12, oxaprozin, The risk or severity of renal failure and hypertension can be increased when Oxaprozin is combined with Cyclosporine.]
[N03AF02, oxcarbazepine, The metabolism of Cyclosporine can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, Dexamethasone may increase the immunosuppressive activities of Cyclosporine.]
[G04BD04, oxybutynin, The metabolism of Cyclosporine can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Cyclosporine.]
[L04AB04, adalimumab, The serum concentration of Cyclosporine can be decreased when it is combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Cyclosporine.]
[N06BA02, dextroamphetamine, The metabolism of Amphetamine can be decreased when combined with Cyclosporine.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Cyclosporine.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Cyclosporine.]
[N06AB05, paroxetine, The metabolism of Paroxetine can be decreased when combined with Cyclosporine.]
[B01AC04, clopidogrel, The metabolism of Cyclosporine can be decreased when combined with Clopidogrel.]
[C01DA05, pentaerythritol tetranitrate, Cyclosporine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[P03AC04, permethrin, Cyclosporine may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The metabolism of Cyclosporine can be decreased when combined with Diazepam.]
[N03AX07, phenacemide, The therapeutic efficacy of Phenacemide can be decreased when used in combination with Cyclosporine.]
[V03AH01, diazoxide, The risk or severity of renal failure can be increased when Diazoxide is combined with Cyclosporine.]
[N03AD02, phensuximide, The therapeutic efficacy of Phensuximide can be decreased when used in combination with Cyclosporine.]
[N06AA08, dibenzepin, The risk or severity of hypertension can be increased when Cyclosporine is combined with Dibenzepin.]
[R05DA08, pholcodine, Cyclosporine may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[M05BA02, clodronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Clodronic acid.]
[S01EC02, dichlorphenamide, The risk or severity of renal failure can be increased when Diclofenamide is combined with Cyclosporine.]
[S01BC03, diclofenac, The serum concentration of Diclofenac can be increased when it is combined with Cyclosporine.]
[J01CF01, dicloxacillin, The metabolism of Cyclosporine can be increased when combined with Dicloxacillin.]
[J05AD01, foscarnet, Foscarnet may increase the nephrotoxic activities of Cyclosporine.]
[A03AA07, dicyclomine, Cyclosporine may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF03, zalcitabine, The excretion of Zalcitabine can be decreased when combined with Cyclosporine.]
[A07AB02, phthalylsulfathiazole, The risk or severity of renal failure can be increased when Phthalylsulfathiazole is combined with Cyclosporine.]
[J05AF02, didanosine, Cyclosporine may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[C02DG01, pinacidil, The metabolism of Pinacidil can be decreased when combined with Cyclosporine.]
[A03AX04, pinaverium, The metabolism of Pinaverium can be decreased when combined with Cyclosporine.]
[A10BG03, pioglitazone, The metabolism of Pioglitazone can be decreased when combined with Cyclosporine.]
[N05AD05, pipamperone, Cyclosporine may increase the neurotoxic activities of Pipamperone.]
[L01DC04, ixabepilone, Ixabepilone may increase the immunosuppressive activities of Cyclosporine.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Cyclosporine.]
[L01DB08, pirarubicin, Pirarubicin may increase the immunosuppressive activities of Cyclosporine.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Pirbuterol.]
[C03CA03, piretanide, The risk or severity of renal failure can be increased when Piretanide is combined with Cyclosporine.]
[A08AA03, diethylpropion, The risk or severity of hypertension can be increased when Cyclosporine is combined with Diethylpropion.]
[L02AA01, diethylstilbestrol, The metabolism of Cyclosporine can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Cyclosporine can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, Difluocortolone may increase the immunosuppressive activities of Cyclosporine.]
[N02BA11, diflunisal, The risk or severity of renal failure and hypertension can be increased when Diflunisal is combined with Cyclosporine.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Cyclosporine.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Cyclosporine.]
[C02DB01, dihydralazine, Cyclosporine may decrease the antihypertensive activities of Dihydralazine.]
[C10AX09, ezetimibe, The serum concentration of Cyclosporine can be increased when it is combined with Ezetimibe.]
[L01XX24, pegaspargase, Pegaspargase may increase the immunosuppressive activities of Cyclosporine.]
[C04AE04, dihydroergocristine, The metabolism of Cyclosporine can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Cyclosporine.]
[N02AA03, hydromorphone, Cyclosporine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, Lenalidomide may increase the immunosuppressive activities of Cyclosporine.]
[J05AE08, atazanavir, The metabolism of Cyclosporine can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Cyclosporine may decrease the antihypertensive activities of Treprostinil.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Cyclosporine.]
[V03AB04, pralidoxime, Cyclosporine may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D07AC18, prednicarbate, The risk or severity of adverse effects can be increased when Prednicarbate is combined with Cyclosporine.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be decreased when combined with Cyclosporine.]
[V03AB09, dimercaprol, Cyclosporine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Procaterol.]
[M02AX03, dimethyl sulfoxide, The metabolism of Cyclosporine can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The therapeutic efficacy of Progabide can be decreased when used in combination with Cyclosporine.]
[N02BB04, propyphenazone, The risk or severity of renal failure and hypertension can be increased when Propyphenazone is combined with Cyclosporine.]
[M01AB14, proglumetacin, The risk or severity of renal failure and hypertension can be increased when Proglumetacin is combined with Cyclosporine.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Cyclosporine.]
[C05CA03, diosmin, The serum concentration of Cyclosporine can be increased when it is combined with Diosmin.]
[R06AA02, diphenhydramine, The metabolism of Diphenhydramine can be decreased when combined with Cyclosporine.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Cyclosporine.]
[C09AA06, quinapril, Cyclosporine may decrease the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, Cyclosporine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N06BA11, dexmethylphenidate, The risk or severity of hypertension can be increased when Cyclosporine is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Quinupramine.]
[A03FA02, cisapride, The metabolism of Cyclosporine can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Cyclosporine may decrease the antihypertensive activities of Ramipril.]
[S01XA23, sirolimus, Sirolimus may increase the immunosuppressive activities of Cyclosporine.]
[N05AL04, remoxipride, The metabolism of Remoxipride can be decreased when combined with Cyclosporine.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Reproterol.]
[S01AX06, resorcinol, Cyclosporine may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The metabolism of Disopyramide can be decreased when combined with Cyclosporine.]
[L04AA23, natalizumab, Natalizumab may increase the immunosuppressive activities of Cyclosporine.]
[P03AA04, disulfiram, The metabolism of Cyclosporine can be decreased when combined with Disulfiram.]
[S02AA12, rifamycin SV, The serum concentration of Cyclosporine can be increased when it is combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Cyclosporine can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The serum concentration of Rifaximin can be increased when it is combined with Cyclosporine.]
[N07XX02, riluzole, Cyclosporine may decrease the excretion rate of Riluzole which could result in a higher serum level.]
[N05AX08, risperidone, The metabolism of Risperidone can be decreased when combined with Cyclosporine.]
[R06AE09, levocetirizine, The metabolism of Levocetirizine can be decreased when combined with Cyclosporine.]
[L04AA21, efalizumab, Efalizumab may increase the immunosuppressive activities of Cyclosporine.]
[N01BB09, ropivacaine, Cyclosporine may decrease the excretion rate of Ropivacaine which could result in a higher serum level.]
[J01MB01, rosoxacin, The risk or severity of nephrotoxicity can be increased when Rosoxacin is combined with Cyclosporine.]
[L01EX01, sunitinib, Sunitinib may increase the immunosuppressive activities of Cyclosporine.]
[A04AD12, aprepitant, The metabolism of Cyclosporine can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Cyclosporine.]
[L01XG01, bortezomib, Bortezomib may increase the immunosuppressive activities of Cyclosporine.]
[J05AE07, fosamprenavir, The metabolism of Cyclosporine can be decreased when combined with Fosamprenavir.]
[G04BE08, tadalafil, The metabolism of Cyclosporine can be decreased when combined with Tadalafil.]
[S01BC05, ketorolac, The risk or severity of renal failure and hypertension can be increased when Ketorolac is combined with Cyclosporine.]
[C02KX02, ambrisentan, The serum concentration of Ambrisentan can be increased when it is combined with Cyclosporine.]
[C01EB18, ranolazine, The serum concentration of Ranolazine can be increased when it is combined with Cyclosporine.]
[N02BA06, salsalate, The risk or severity of renal failure and hypertension can be increased when Salsalate is combined with Cyclosporine.]
[R03AC12, salmeterol, The metabolism of Cyclosporine can be decreased when combined with Salmeterol.]
[H05BA01, salmon calcitonin, Cyclosporine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.]
[C01CA07, dobutamine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Dobutamine.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Cyclosporine.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Dopamine.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Cyclosporine.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Cyclosporine is combined with Doxapram.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Cyclosporine.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be increased when it is combined with Cyclosporine.]
[J01AA02, doxycycline, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Doxycycline.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Cyclosporine.]
[N01AB08, sevoflurane, The risk or severity of hypertension can be increased when Cyclosporine is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Droperidol.]
[A08AA10, sibutramine, The metabolism of Sibutramine can be decreased when combined with Cyclosporine.]
[C10AA01, simvastatin, The serum concentration of Simvastatin can be increased when it is combined with Cyclosporine.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Cyclosporine.]
[A12CA02, sodium sulfate, Cyclosporine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, Cyclosporine may decrease the antihypertensive activities of Spirapril.]
[G03DB01, dydrogesterone, The metabolism of Dydrogesterone can be decreased when combined with Cyclosporine.]
[R03DA01, dyphylline, Cyclosporine may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[A07AB04, succinylsulfathiazole, The risk or severity of renal failure can be increased when Succinylsulfathiazole is combined with Cyclosporine.]
[N05AL02, sultopride, Cyclosporine may increase the neurotoxic activities of Sultopride.]
[N02CC01, sumatriptan, The risk or severity of renal failure can be increased when Sumatriptan is combined with Cyclosporine.]
[V04CX07, edrophonium, Cyclosporine may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The metabolism of Talinolol can be decreased when combined with Cyclosporine.]
[H01AA01, corticotropin, Corticotropin may increase the immunosuppressive activities of Cyclosporine.]
[J01CG02, tazobactam, The excretion of Tazobactam can be decreased when combined with Cyclosporine.]
[J01MA05, temafloxacin, The risk or severity of nephrotoxicity can be increased when Temafloxacin is combined with Cyclosporine.]
[L01AX03, temozolomide, Temozolomide may increase the immunosuppressive activities of Cyclosporine.]
[M01AC02, tenoxicam, The risk or severity of renal failure and hypertension can be increased when Tenoxicam is combined with Cyclosporine.]
[G04CA03, terazosin, Cyclosporine may decrease the antihypertensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Cyclosporine can be increased when combined with Terbinafine.]
[G04BD05, terodiline, The metabolism of Terodiline can be decreased when combined with Cyclosporine.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Cyclosporine.]
[A08AB01, orlistat, Orlistat can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Cyclosporine is combined with Tetryzoline.]
[N05AB05, thiopropazate, Cyclosporine may increase the neurotoxic activities of Thiopropazate.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Emetine.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Cyclosporine.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of renal failure and hypertension can be increased when Tolfenamic acid is combined with Cyclosporine.]
[N06AG03, toloxatone, The risk or severity of hypertension can be increased when Cyclosporine is combined with Toloxatone.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Cyclosporine.]
[N03AX11, topiramate, The metabolism of Cyclosporine can be increased when combined with Topiramate.]
[L02BA02, toremifene, The serum concentration of Cyclosporine can be increased when it is combined with Toremifene.]
[C03CA04, torsemide, The risk or severity of renal failure can be increased when Torasemide is combined with Cyclosporine.]
[J01AA12, tigecycline, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Tigecycline.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Cyclosporine is combined with Tramazoline.]
[C09AA10, trandolapril, Cyclosporine may decrease the antihypertensive activities of Trandolapril.]
[H02CA01, trilostane, Trilostane may increase the immunosuppressive activities of Cyclosporine.]
[L01AA07, trofosfamide, Trofosfamide may increase the immunosuppressive activities of Cyclosporine.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Tulobuterol.]
[C02CA06, urapidil, Cyclosporine may decrease the antihypertensive activities of Urapidil.]
[J01MA04, enoxacin, The risk or severity of nephrotoxicity can be increased when Enoxacin is combined with Cyclosporine.]
[N05AL06, veralipride, Cyclosporine may increase the neurotoxic activities of Veralipride.]
[L01CA04, vinorelbine, Vinorelbine may increase the immunosuppressive activities of Cyclosporine.]
[S01FB02, ephedrine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Ephedrine.]
[S01GX10, epinastine, The metabolism of Epinastine can be decreased when combined with Cyclosporine.]
[N06AX16, venlafaxine, The metabolism of Venlafaxine can be decreased when combined with Cyclosporine.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Cyclosporine is combined with Xylometazoline.]
[C08CA12, mepirodipine, The serum concentration of Barnidipine can be increased when it is combined with Cyclosporine.]
[S01EA01, epinephrine, The metabolism of Cyclosporine can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, Epirubicin may increase the immunosuppressive activities of Cyclosporine.]
[C09AA15, zofenopril, Cyclosporine may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Cyclosporine.]
[M01AB04, zomepirac, The risk or severity of renal failure and hypertension can be increased when Zomepirac is combined with Cyclosporine.]
[N03AX15, zonisamide, The risk or severity of renal failure can be increased when Zonisamide is combined with Cyclosporine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Cyclosporine.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Cyclosporine.]
[L01XA02, carboplatin, Carboplatin may increase the immunosuppressive activities of Cyclosporine.]
[C02AC02, guanfacine, The metabolism of Guanfacine can be decreased when combined with Cyclosporine.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Iloprost.]
[C01BG01, moricizine, Cyclosporine may increase the neurotoxic activities of Moricizine.]
[G02AB03, ergonovine, The metabolism of Ergometrine can be decreased when combined with Cyclosporine.]
[C04AE01, ergoloid mesylates, USP, The metabolism of Ergoloid mesylate can be decreased when combined with Cyclosporine.]
[N02CA02, ergotamine, The metabolism of Cyclosporine can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Cyclosporine may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The metabolism of Cyclosporine can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The metabolism of Estazolam can be decreased when combined with Cyclosporine.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be decreased when combined with Cyclosporine.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be decreased when combined with Cyclosporine.]
[G03CA03, estradiol, The metabolism of Cyclosporine can be decreased when combined with Estradiol.]
[L01XX11, estramustine, Estramustine may increase the immunosuppressive activities of Cyclosporine.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Conjugated estrogens can be decreased when combined with Cyclosporine.]
[J04AK02, ethambutol, The metabolism of Cyclosporine can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, Fluticasone furoate may increase the immunosuppressive activities of Cyclosporine.]
[R03BA05, fluticasone, Fluticasone may increase the immunosuppressive activities of Cyclosporine.]
[C10AA04, fluvastatin, The serum concentration of Fluvastatin can be increased when it is combined with Cyclosporine.]
[V08CA03, gadodiamide, Cyclosporine may decrease the excretion rate of Gadodiamide which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Gepefrine.]
[D07AC21, halobetasol, The risk or severity of adverse effects can be increased when Ulobetasol is combined with Cyclosporine.]
[L02AA03, ethinyl estradiol, The metabolism of Cyclosporine can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, Cyclosporine may decrease the excretion rate of Ibutilide which could result in a higher serum level.]
[N03AD01, ethosuximide, The metabolism of Ethosuximide can be decreased when combined with Cyclosporine.]
[N03AB01, ethotoin, The therapeutic efficacy of Ethotoin can be decreased when used in combination with Cyclosporine.]
[M01AC06, meloxicam, The risk or severity of renal failure and hypertension can be increased when Meloxicam is combined with Cyclosporine.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Cyclosporine.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of hypertension can be increased when Cyclosporine is combined with Etomidate.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Cyclosporine.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Cyclosporine.]
[L04AD02, tacrolimus, Tacrolimus may increase the nephrotoxic activities of Cyclosporine.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Nizatidine.]
[J01MA08, fleroxacin, The risk or severity of nephrotoxicity can be increased when Fleroxacin is combined with Cyclosporine.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Cyclosporine.]
[R06AX12, terfenadine, The metabolism of Cyclosporine can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Cyclosporine may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of seizure can be increased when Bupropion is combined with Cyclosporine.]
[N06AB08, fluvoxamine, The metabolism of Fluvoxamine can be decreased when combined with Cyclosporine.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Cyclosporine.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cyclosporine.]
[L04AA02, muromonab-CD3, Muromonab may increase the immunosuppressive activities of Cyclosporine.]
[C10AA03, pravastatin, The serum concentration of Pravastatin can be increased when it is combined with Cyclosporine.]
[M01CB01, gold sodium thiomalate, Cyclosporine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Cyclosporine may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may increase the immunosuppressive activities of Cyclosporine.]
[A16AA01, levocarnitine, Cyclosporine may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Cyclosporine can be decreased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Cyclosporine can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The metabolism of Fendiline can be decreased when combined with Cyclosporine.]
[N03AX26, fenfluramine, The metabolism of Fenfluramine can be decreased when combined with Cyclosporine.]
[M01AE04, fenoprofen, The risk or severity of renal failure and hypertension can be increased when Fenoprofen is combined with Cyclosporine.]
[R03CC04, fenoterol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Fenoterol.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Cyclosporine.]
[R03CC02, albuterol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Salbutamol.]
[L01BB06, clofarabine, Clofarabine may increase the immunosuppressive activities of Cyclosporine.]
[L04AA40, cladribine, Cladribine may increase the immunosuppressive activities of Cyclosporine.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Cyclosporine.]
[G04BD02, flavoxate, Cyclosporine may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Cyclosporine.]
[N02BG04, floctafenine, The risk or severity of renal failure and hypertension can be increased when Floctafenine is combined with Cyclosporine.]
[J01CF05, floxacillin, The metabolism of Cyclosporine can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The serum concentration of Cyclosporine can be increased when it is combined with Fluconazole.]
[J02AX01, flucytosine, Flucytosine may increase the immunosuppressive activities of Cyclosporine.]
[H02AA02, fludrocortisone, Fludrocortisone may increase the immunosuppressive activities of Cyclosporine.]
[V03AB25, flumazenil, Cyclosporine may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, Flumethasone may increase the immunosuppressive activities of Cyclosporine.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Cyclosporine.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Cyclosporine.]
[D07AC08, fluocinonide, Fluocinonide may increase the immunosuppressive activities of Cyclosporine.]
[N06AA14, melitracen, The risk or severity of hypertension can be increased when Cyclosporine is combined with Melitracen.]
[H02AB03, fluocortolone, Fluocortolone may increase the immunosuppressive activities of Cyclosporine.]
[V03AZ01, ethanol, The metabolism of Cyclosporine can be increased when combined with Ethanol.]
[L01BC09, floxuridine, Floxuridine may increase the immunosuppressive activities of Cyclosporine.]
[S01CB05, fluorometholone, Fluorometholone may increase the immunosuppressive activities of Cyclosporine.]
[L01BC02, fluorouracil, Fluorouracil may increase the immunosuppressive activities of Cyclosporine.]
[N06AB03, fluoxetine, The metabolism of Fluoxetine can be decreased when combined with Cyclosporine.]
[G03BA01, fluoxymesterone, The risk or severity of liver damage can be increased when Fluoxymesterone is combined with Cyclosporine.]
[N05AF01, flupenthixol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Flupentixol.]
[N05AB02, fluphenazine, Cyclosporine may increase the neurotoxic activities of Fluphenazine.]
[D07AC07, flurandrenolide, The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Cyclosporine.]
[N05CD01, flurazepam, The metabolism of Flurazepam can be decreased when combined with Cyclosporine.]
[S01BC04, flurbiprofen, The risk or severity of renal failure and hypertension can be increased when Flurbiprofen is combined with Cyclosporine.]
[N05AG01, fluspirilene, The metabolism of Fluspirilene can be decreased when combined with Cyclosporine.]
[L02BB01, flutamide, The metabolism of Cyclosporine can be decreased when combined with Flutamide.]
[V04CX02, folic acid, Cyclosporine may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[S02AA17, fosfomycin, Cyclosporine may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Framycetin.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Cyclosporine.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Cyclosporine is combined with Adrafinil.]
[M03AA01, alcuronium, The therapeutic efficacy of Alcuronium can be increased when used in combination with Cyclosporine.]
[G01AX06, furazolidone, The risk or severity of hypertension can be increased when Cyclosporine is combined with Furazolidone.]
[J05AE10, darunavir, The serum concentration of Cyclosporine can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, The risk or severity of gouty arthritis can be increased when Cyclosporine is combined with Furosemide.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Cyclosporine.]
[N05AL05, amisulpride, Cyclosporine may increase the neurotoxic activities of Amisulpride.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Cyclosporine.]
[M03AC02, gallamine, The therapeutic efficacy of Gallamine can be increased when used in combination with Cyclosporine.]
[C08DA02, gallopamil, The metabolism of Gallopamil can be decreased when combined with Cyclosporine.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Ganciclovir.]
[N03AA04, barbexaclone, The metabolism of Cyclosporine can be increased when combined with Barbexaclone.]
[C10AB04, gemfibrozil, The risk or severity of renal failure can be increased when Cyclosporine is combined with Gemfibrozil.]
[J01XA03, telavancin, Cyclosporine may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[L01EA02, dasatinib, Dasatinib may increase the immunosuppressive activities of Cyclosporine.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Cyclosporine.]
[J05AG04, etravirine, The metabolism of Cyclosporine can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Cyclosporine.]
[G03XA02, gestrinone, The metabolism of Cyclosporine can be decreased when combined with Gestrinone.]
[N01AH02, alfentanil, The metabolism of Cyclosporine can be decreased when combined with Alfentanil.]
[L01EH01, lapatinib, The serum concentration of Cyclosporine can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Cyclosporine.]
[A10BB07, glipizide, Cyclosporine may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Dexmedetomidine.]
[C05AE01, nitroglycerin, Cyclosporine may decrease the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Cyclosporine.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Cyclosporine.]
[L01EX02, sorafenib, Sorafenib may increase the immunosuppressive activities of Cyclosporine.]
[C07AB09, esmolol, The metabolism of Esmolol can be decreased when combined with Cyclosporine.]
[M01CB04, aurothioglucose, Cyclosporine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Cyclosporine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, Cyclosporine may decrease the antihypertensive activities of Fosinopril.]
[D01BA01, griseofulvin, The serum concentration of Cyclosporine can be decreased when it is combined with Griseofulvin.]
[S01EX01, guanethidine, Cyclosporine may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, Cyclosporine may decrease the excretion rate of Goserelin which could result in a higher serum level.]
[P01BX01, halofantrine, The metabolism of Cyclosporine can be decreased when combined with Halofantrine.]
[D07AD02, halcinonide, The risk or severity of adverse effects can be increased when Halcinonide is combined with Cyclosporine.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Cyclosporine.]
[N01AB01, halothane, The risk or severity of hypertension can be increased when Cyclosporine is combined with Halothane.]
[N05AH04, quetiapine, The metabolism of Quetiapine can be decreased when combined with Cyclosporine.]
[N06BX13, idebenone, Cyclosporine may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[L01CE02, irinotecan, Irinotecan may increase the immunosuppressive activities of Cyclosporine.]
[M04AA01, allopurinol, The serum concentration of Cyclosporine can be increased when it is combined with Allopurinol.]
[C09CA01, losartan, The risk or severity of hyperkalemia can be increased when Losartan is combined with Cyclosporine.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Heparin.]
[B05CB03, magnesium citrate, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium citrate.]
[A12CC03, magnesium gluconate, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium gluconate.]
[G03DC01, allylestrenol, The metabolism of Cyclosporine can be decreased when combined with Allylestrenol.]
[A07EC02, mesalamine, The risk or severity of renal failure and hypertension can be increased when Mesalazine is combined with Cyclosporine.]
[C01CE02, milrinone, Cyclosporine may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[L01XX03, altretamine, Altretamine may increase the immunosuppressive activities of Cyclosporine.]
[N05CA16, hexobarbital, The metabolism of Cyclosporine can be increased when combined with Hexobarbital.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Cyclosporine is combined with Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Cyclosporine.]
[C08CA10, nilvadipine, The metabolism of Cyclosporine can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of renal failure and hypertension can be increased when Nimesulide is combined with Cyclosporine.]
[C09AA04, perindopril, Cyclosporine may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, The metabolism of Cyclosporine can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of renal failure can be increased when Hydrochlorothiazide is combined with Cyclosporine.]
[R05DA03, hydrocodone, The metabolism of Hydrocodone can be decreased when combined with Cyclosporine.]
[S02BA01, hydrocortisone, Hydrocortisone may increase the immunosuppressive activities of Cyclosporine.]
[D07AC16, hydrocortisone aceponate, The risk or severity of adverse effects can be increased when Hydrocortisone aceponate is combined with Cyclosporine.]
[C03AA02, hydroflumethiazide, The risk or severity of renal failure can be increased when Hydroflumethiazide is combined with Cyclosporine.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Cyclosporine.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Cyclosporine.]
[A12BA02, potassium citrate, Potassium citrate may increase the hyperkalemic activities of Cyclosporine.]
[V03AB33, hydroxocobalamin, Cyclosporine may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.]
[G04BD06, propiverine, The metabolism of Propiverine can be decreased when combined with Cyclosporine.]
[P01BA02, hydroxychloroquine, Hydroxychloroquine may increase the immunosuppressive activities of Cyclosporine.]
[N05AX07, prothipendyl, Cyclosporine may increase the neurotoxic activities of Prothipendyl.]
[B05AA07, hetastarch, Cyclosporine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[G03DA03, 17-alpha-hydroxyprogesterone, The metabolism of Hydroxyprogesterone can be decreased when combined with Cyclosporine.]
[L01XX05, hydroxyurea, Hydroxyurea may increase the immunosuppressive activities of Cyclosporine.]
[N05BB01, hydroxyzine, The metabolism of Cyclosporine can be decreased when combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Cyclosporine can be increased when combined with Rifabutin.]
[C02AC06, rilmenidine, Cyclosporine may decrease the antihypertensive activities of Rilmenidine.]
[S01BA13, rimexolone, The risk or severity of adverse effects can be increased when Rimexolone is combined with Cyclosporine.]
[M05BA07, risedronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of renal failure and hypertension can be increased when Ibuprofen is combined with Cyclosporine.]
[B05XA08, sodium acetate, Cyclosporine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, Cyclosporine may increase the neurotoxic activities of Sodium citrate.]
[L01DB06, idarubicin, Idarubicin may increase the immunosuppressive activities of Cyclosporine.]
[L01AA06, ifosfamide, Ifosfamide may increase the immunosuppressive activities of Cyclosporine.]
[N01AH03, sufentanil, The metabolism of Sufentanil can be decreased when combined with Cyclosporine.]
[N06AA02, imipramine, The metabolism of Imipramine can be decreased when combined with Cyclosporine.]
[L01CD01, paclitaxel, Paclitaxel may increase the immunosuppressive activities of Cyclosporine.]
[R01AD07, tixocortol, Tixocortol may increase the immunosuppressive activities of Cyclosporine.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Cyclosporine.]
[L01CE01, topotecan, Topotecan may increase the immunosuppressive activities of Cyclosporine.]
[C03BA11, indapamide, The risk or severity of renal failure can be increased when Indapamide is combined with Cyclosporine.]
[S01BC01, indomethacin, Indomethacin may increase the immunosuppressive activities of Cyclosporine.]
[C02CA02, indoramin, Cyclosporine may decrease the antihypertensive activities of Indoramin.]
[A11HA07, inositol, Cyclosporine may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, Interferon alfa-2a may increase the immunosuppressive activities of Cyclosporine.]
[L03AB05, interferon alfa-2b, Interferon alfa-2b may increase the immunosuppressive activities of Cyclosporine.]
[N06AX17, milnacipran, The metabolism of Cyclosporine can be decreased when combined with Milnacipran.]
[R01AA02, cyclopentamine, The risk or severity of adverse effects can be increased when Cyclosporine is combined with Cyclopentamine.]
[S01XA28, varenicline, Cyclosporine may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[L04AA25, eculizumab, Eculizumab may increase the immunosuppressive activities of Cyclosporine.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be decreased when combined with Cyclosporine.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Cyclosporine.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Cyclosporine.]
[C10AA06, cerivastatin, The metabolism of Cyclosporine can be increased when combined with Cerivastatin.]
[C07AA01, alprenolol, The metabolism of Alprenolol can be decreased when combined with Cyclosporine.]
[C03BA02, quinethazone, The risk or severity of renal failure can be increased when Quinethazone is combined with Cyclosporine.]
[L03AB09, interferon alfacon-1, Interferon alfacon-1 may increase the immunosuppressive activities of Cyclosporine.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Cyclosporine.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Stavudine.]
[N06AA13, iprindole, The risk or severity of hypertension can be increased when Cyclosporine is combined with Iprindole.]
[G04BE01, alprostadil, The excretion of Alprostadil can be decreased when combined with Cyclosporine.]
[N06AF05, iproniazid, The risk or severity of hypertension can be increased when Cyclosporine is combined with Iproniazid.]
[N05AA07, chlorproethazine, Cyclosporine may increase the neurotoxic activities of Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of hypertension can be increased when Cyclosporine is combined with Isocarboxazid.]
[P01AX06, atovaquone, The metabolism of Atovaquone can be decreased when combined with Cyclosporine.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoetharine.]
[C09AA16, imidapril, Cyclosporine may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoflurane.]
[J04AC01, isoniazid, The metabolism of Cyclosporine can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Cyclosporine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoprenaline.]
[D10BA01, isotretinoin, The metabolism of Isotretinoin can be decreased when combined with Cyclosporine.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoxsuprine.]
[P02CF01, ivermectin, The metabolism of Ivermectin can be decreased when combined with Cyclosporine.]
[J01FA07, josamycin, The metabolism of Cyclosporine can be decreased when combined with Josamycin.]
[N06AX18, reboxetine, The metabolism of Reboxetine can be decreased when combined with Cyclosporine.]
[S01AA24, kanamycin, Cyclosporine may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Cyclosporine.]
[L04AC07, tocilizumab, Tocilizumab may increase the immunosuppressive activities of Cyclosporine.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Cyclosporine.]
[C02KD01, ketanserin, Cyclosporine may decrease the antihypertensive activities of Ketanserin.]
[B01AC22, prasugrel, Cyclosporine may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, Ketoconazole may increase the nephrotoxic activities of Cyclosporine.]
[N05AH03, olanzapine, The metabolism of Olanzapine can be decreased when combined with Cyclosporine.]
[M02AA10, ketoprofen, The risk or severity of renal failure and hypertension can be increased when Ketoprofen is combined with Cyclosporine.]
[V03AC03, deferasirox, The metabolism of Cyclosporine can be increased when combined with Deferasirox.]
[L04AA24, abatacept, Abatacept may increase the immunosuppressive activities of Cyclosporine.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Arbutamine.]
[N04BC09, rotigotine, The metabolism of Rotigotine can be decreased when combined with Cyclosporine.]
[J01MB02, nalidixic acid, The risk or severity of nephrotoxicity can be increased when Nalidixic acid is combined with Cyclosporine.]
[M01AE11, tiaprofenic acid, The risk or severity of renal failure and hypertension can be increased when Tiaprofenic acid is combined with Cyclosporine.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Cyclosporine.]
[N04BB01, amantadine, Cyclosporine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J05AX09, maraviroc, The metabolism of Maraviroc can be decreased when combined with Cyclosporine.]
[C02AA05, deserpidine, Cyclosporine may decrease the antihypertensive activities of Deserpidine.]
[A06AX03, lubiprostone, Cyclosporine may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The metabolism of Cyclosporine can be decreased when combined with Lacosamide.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Cyclosporine is combined with Etacrynic acid.]
[R05CB06, ambroxol, The metabolism of Ambroxol can be decreased when combined with Cyclosporine.]
[L01DC03, mitomycin, Mitomycin may increase the immunosuppressive activities of Cyclosporine.]
[G03AD01, levonorgestrel, The metabolism of Cyclosporine can be decreased when combined with Levonorgestrel.]
[S02DA01, lidocaine, The metabolism of Lidocaine can be decreased when combined with Cyclosporine.]
[C08EX01, lidoflazine, The metabolism of Lidoflazine can be decreased when combined with Cyclosporine.]
[J01FF02, lincomycin, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Lincomycin.]
[S01AA21, amikacin, Cyclosporine may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Cyclosporine.]
[C03DB01, amiloride, The risk or severity of hyperkalemia can be increased when Amiloride is combined with Cyclosporine.]
[N02CA07, lisuride, The metabolism of Lisuride can be decreased when combined with Cyclosporine.]
[N06AA07, lofepramine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Lofepramine.]
[L01AD02, lomustine, Lomustine may increase the immunosuppressive activities of Cyclosporine.]
[A07DA03, loperamide, The excretion of Loperamide can be decreased when combined with Cyclosporine.]
[N05BA06, lorazepam, The metabolism of Lorazepam can be decreased when combined with Cyclosporine.]
[C10AA02, lovastatin, The serum concentration of Lovastatin can be increased when it is combined with Cyclosporine.]
[N05AH01, loxapine, The serum concentration of Cyclosporine can be increased when it is combined with Loxapine.]
[J01AA04, lymecycline, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Lymecycline.]
[G03DC03, lynestrenol, The metabolism of Cyclosporine can be decreased when combined with Lynestrenol.]
[L01EG01, temsirolimus, Temsirolimus may increase the immunosuppressive activities of Cyclosporine.]
[B05XA11, magnesium chloride, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium chloride.]
[G04BX01, magnesium hydroxide, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Cyclosporine.]
[L01BA05, pralatrexate, Pralatrexate may increase the immunosuppressive activities of Cyclosporine.]
[L01EA03, nilotinib, Nilotinib may increase the immunosuppressive activities of Cyclosporine.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cyclosporine.]
[N06AA21, maprotiline, The metabolism of Maprotiline can be decreased when combined with Cyclosporine.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Cyclosporine is combined with Mecamylamine.]
[L01AA05, mechlorethamine, Mechlorethamine may increase the immunosuppressive activities of Cyclosporine.]
[R06AE05, meclizine, The metabolism of Meclizine can be decreased when combined with Cyclosporine.]
[M02AA18, meclofenamic acid, The risk or severity of renal failure and hypertension can be increased when Meclofenamic acid is combined with Cyclosporine.]
[N05BA03, medazepam, The therapeutic efficacy of Medazepam can be decreased when used in combination with Cyclosporine.]
[C01AA08, medigoxin, The serum concentration of Metildigoxin can be increased when it is combined with Cyclosporine.]
[G03DB03, medrogestone, The metabolism of Medrogestone can be decreased when combined with Cyclosporine.]
[P01BC02, mefloquine, The serum concentration of Cyclosporine can be increased when it is combined with Mefloquine.]
[C03BA05, mefruside, The risk or severity of renal failure can be increased when Mefruside is combined with Cyclosporine.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Dalteparin.]
[L01AA03, melphalan, Melphalan may increase the nephrotoxic activities of Cyclosporine.]
[N06DX01, memantine, Cyclosporine may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, The metabolism of Cyclosporine can be decreased when combined with Meperidine.]
[C01CA11, mephentermine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Mephentermine.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Cyclosporine.]
[N03AA01, mephobarbital, The metabolism of Cyclosporine can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, Cyclosporine may decrease the excretion rate of Mepivacaine which could result in a higher serum level.]
[G04BX16, tiopronin, Cyclosporine may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[L02BG01, aminoglutethimide, The metabolism of Cyclosporine can be increased when combined with Aminoglutethimide.]
[C03BC01, mersalyl, Cyclosporine may decrease the excretion rate of Mersalyl which could result in a higher serum level.]
[N05AC03, mesoridazine, The metabolism of Mesoridazine can be decreased when combined with Cyclosporine.]
[G03BB01, mesterolone, The risk or severity of liver damage can be increased when Mesterolone is combined with Cyclosporine.]
[N05AX13, paliperidone, The metabolism of Paliperidone can be decreased when combined with Cyclosporine.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Metaraminol.]
[A10BA02, metformin, Cyclosporine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[A04AA04, dolasetron, The metabolism of Dolasetron can be decreased when combined with Cyclosporine.]
[H01CB03, lanreotide, The bioavailability of Cyclosporine can be decreased when combined with Lanreotide.]
[J01AA05, methacycline, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Metacycline.]
[N07BC02, methadone, The metabolism of Methadone can be decreased when combined with Cyclosporine.]
[N06BA03, methamphetamine, The metabolism of Metamfetamine can be decreased when combined with Cyclosporine.]
[N05CM01, methaqualone, The metabolism of Methaqualone can be decreased when combined with Cyclosporine.]
[J05AF05, lamivudine, Cyclosporine may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[N03AA30, metharbital, The therapeutic efficacy of Metharbital can be decreased when used in combination with Cyclosporine.]
[S01EC05, methazolamide, The risk or severity of renal failure can be increased when Methazolamide is combined with Cyclosporine.]
[G02CB05, metergoline, The risk or severity of hypertension can be increased when Cyclosporine is combined with Metergoline.]
[H03BB02, methimazole, Methimazole may increase the immunosuppressive activities of Cyclosporine.]
[L01BA04, pemetrexed, Pemetrexed may increase the immunosuppressive activities of Cyclosporine.]
[N05CA15, methohexital, The metabolism of Cyclosporine can be increased when combined with Methohexital.]
[A11HA02, pyridoxine, Cyclosporine may decrease the excretion rate of Pyridoxine which could result in a higher serum level.]
[L04AX03, methotrexate, The serum concentration of Methotrexate can be increased when it is combined with Cyclosporine.]
[N05AA02, methotrimeprazine, The metabolism of Methotrimeprazine can be decreased when combined with Cyclosporine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Methoxamine.]
[D05BA02, methoxsalen, Cyclosporine may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Cyclosporine.]
[C03AA08, methyclothiazide, The risk or severity of renal failure can be increased when Methyclothiazide is combined with Cyclosporine.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Methyldopa.]
[V04CG05, methylene blue, The metabolism of Methylene blue can be decreased when combined with Cyclosporine.]
[G02AB01, methylergonovine, The metabolism of Cyclosporine can be decreased when combined with Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Cyclosporine.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Cyclosporine is combined with Methylphenidate.]
[H02AB04, methylprednisolone, The serum concentration of Methylprednisolone can be increased when it is combined with Cyclosporine.]
[D07AC14, methylprednisolone aceponate, The risk or severity of adverse effects can be increased when Methylprednisolone aceponate is combined with Cyclosporine.]
[N03AF03, rufinamide, The metabolism of Cyclosporine can be increased when combined with Rufinamide.]
[G03EK01, methyltestosterone, The risk or severity of liver damage can be increased when Methyltestosterone is combined with Cyclosporine.]
[N02CA04, methysergide, The metabolism of Cyclosporine can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, Metoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C03BA08, metolazone, The risk or severity of renal failure can be increased when Metolazone is combined with Cyclosporine.]
[C07AB02, metoprolol, The metabolism of Metoprolol can be decreased when combined with Cyclosporine.]
[P01AB01, metronidazole, The metabolism of Cyclosporine can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Cyclosporine can be increased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Cyclosporine.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Cyclosporine.]
[S02AA13, miconazole, The metabolism of Cyclosporine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of renal failure and hypertension can be increased when Aminophenazone is combined with Cyclosporine.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Parnaparin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Cyclosporine.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Midodrine.]
[G03XB01, mifepristone, The serum concentration of Cyclosporine can be increased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Tinzaparin.]
[J05AH01, zanamivir, Cyclosporine may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of hyperkalemia can be increased when Valsartan is combined with Cyclosporine.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Minocycline.]
[D11AX01, minoxidil, The risk or severity of Hypertrichosis can be increased when Cyclosporine is combined with Minoxidil.]
[J01FA11, miocamycin, The metabolism of Cyclosporine can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Cyclosporine can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The serum concentration of Mitoxantrone can be increased when it is combined with Cyclosporine.]
[N06BA12, lisdexamfetamine, The metabolism of Lisdexamfetamine can be decreased when combined with Cyclosporine.]
[N05AE02, molindone, Cyclosporine may increase the neurotoxic activities of Molindone.]
[L03AC01, aldesleukin, Aldesleukin may increase the immunosuppressive activities of Cyclosporine.]
[C01BD01, amiodarone, The serum concentration of Cyclosporine can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Cyclosporine.]
[N02AA01, morphine, The metabolism of Morphine can be decreased when combined with Cyclosporine.]
[A04AA05, palonosetron, The metabolism of Palonosetron can be decreased when combined with Cyclosporine.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Latamoxef.]
[L04AB05, certolizumab pegol, Certolizumab pegol may increase the immunosuppressive activities of Cyclosporine.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Ammonium chloride.]
[L04AA52, ofatumumab, Ofatumumab may increase the immunosuppressive activities of Cyclosporine.]
[L01EX03, pazopanib, Pazopanib may increase the immunosuppressive activities of Cyclosporine.]
[L04AA06, mycophenolic acid, Mycophenolic acid may increase the immunosuppressive activities of Cyclosporine.]
[M03AC03, vecuronium, The therapeutic efficacy of Vecuronium can be increased when used in combination with Cyclosporine.]
[N05CA02, amobarbital, The metabolism of Cyclosporine can be increased when combined with Amobarbital.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Raltegravir.]
[G04CA04, silodosin, The excretion of Silodosin can be decreased when combined with Cyclosporine.]
[G03XC01, raloxifene, The metabolism of Cyclosporine can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Cyclosporine.]
[N03AB05, fosphenytoin, The serum concentration of Cyclosporine can be decreased when it is combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, Interferon beta-1b may increase the immunosuppressive activities of Cyclosporine.]
[C07AA12, nadolol, The metabolism of Nadolol can be decreased when combined with Cyclosporine.]
[J01CA04, amoxicillin, Cyclosporine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[J01CF06, nafcillin, The metabolism of Cyclosporine can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Cyclosporine can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Naltrexone.]
[L04AC03, anakinra, Anakinra may increase the immunosuppressive activities of Cyclosporine.]
[S01XA11, nandrolone, The risk or severity of liver damage can be increased when Nandrolone phenpropionate is combined with Cyclosporine.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Cyclosporine is combined with Naphazoline.]
[N06BA01, amphetamine, The metabolism of Amphetamine can be decreased when combined with Cyclosporine.]
[M02AA12, naproxen, The risk or severity of renal failure and hypertension can be increased when Naproxen is combined with Cyclosporine.]
[A10BG01, troglitazone, The metabolism of Cyclosporine can be increased when combined with Troglitazone.]
[N06AX21, duloxetine, The metabolism of Duloxetine can be decreased when combined with Cyclosporine.]
[N04BX01, tolcapone, Cyclosporine may decrease the excretion rate of Tolcapone which could result in a higher serum level.]
[L01CD02, docetaxel, Docetaxel may increase the immunosuppressive activities of Cyclosporine.]
[L02BG04, letrozole, The metabolism of Letrozole can be decreased when combined with Cyclosporine.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Neomycin.]
[N01AH06, remifentanil, The risk or severity of hypertension can be increased when Cyclosporine is combined with Remifentanil.]
[A10BX02, repaglinide, The serum concentration of Repaglinide can be increased when it is combined with Cyclosporine.]
[B01AC17, tirofiban, Cyclosporine may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Cyclosporine.]
[J02AA01, amphotericin B, Amphotericin B may increase the nephrotoxic activities of Cyclosporine.]
[S01AA19, ampicillin, Cyclosporine may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Cyclosporine may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Cyclosporine may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The metabolism of Cyclosporine can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Cyclosporine.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Valaciclovir.]
[H05BX02, paricalcitol, The metabolism of Paricalcitol can be decreased when combined with Cyclosporine.]
[C01CE01, inamrinone, Cyclosporine may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[L01XX01, amsacrine, Amsacrine may increase the immunosuppressive activities of Cyclosporine.]
[C10AD02, niacin, The metabolism of Cyclosporine can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of hypertension can be increased when Cyclosporine is combined with Nialamide.]
[C08CA04, nicardipine, The metabolism of Cyclosporine can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be decreased when combined with Cyclosporine.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Cyclosporine is combined with Nicotine.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Cyclosporine.]
[M02AA17, niflumic acid, The risk or severity of renal failure and hypertension can be increased when Niflumic acid is combined with Cyclosporine.]
[C08CA06, nimodipine, The metabolism of Nimodipine can be decreased when combined with Cyclosporine.]
[C08CA07, nisoldipine, The metabolism of Cyclosporine can be decreased when combined with Nisoldipine.]
[N05CD02, nitrazepam, The metabolism of Nitrazepam can be decreased when combined with Cyclosporine.]
[C08CA08, nitrendipine, The metabolism of Cyclosporine can be decreased when combined with Nitrendipine.]
[R07AX01, nitric oxide, Cyclosporine may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Cyclosporine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The metabolism of Cyclosporine can be decreased when combined with Zaleplon.]
[N04BC05, pramipexole, Cyclosporine may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, Cyclosporine may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of hypertension can be increased when Cyclosporine is combined with Nitrous oxide.]
[C01CA03, norepinephrine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Norepinephrine.]
[G03DC02, norethindrone, The metabolism of Cyclosporine can be decreased when combined with Norethisterone.]
[S01AE02, norfloxacin, The metabolism of Cyclosporine can be decreased when combined with Norfloxacin.]
[G03AC07, norgestrienone, The metabolism of Cyclosporine can be decreased when combined with Norgestrienone.]
[C02KX01, bosentan, The serum concentration of Bosentan can be increased when it is combined with Cyclosporine.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Cyclosporine.]
[R05DA07, noscapine, The metabolism of Cyclosporine can be decreased when combined with Noscapine.]
[A16AX07, sapropterin, The serum concentration of Cyclosporine can be increased when it is combined with Sapropterin.]
[G02CA02, nylidrin, The metabolism of Nylidrin can be decreased when combined with Cyclosporine.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Reviparin.]
[G01AA01, nystatin, The serum concentration of Cyclosporine can be increased when it is combined with Nystatin.]
[H01CB02, octreotide, The serum concentration of Cyclosporine can be increased when it is combined with Octreotide.]
[S02AA16, ofloxacin, The risk or severity of nephrotoxicity can be increased when Ofloxacin is combined with Cyclosporine.]
[J01FA05, oleandomycin, The metabolism of Cyclosporine can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, Rilonacept may increase the immunosuppressive activities of Cyclosporine.]
[A02BC01, omeprazole, The serum concentration of Cyclosporine can be increased when it is combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Opipramol.]
[N02AA02, opium, The metabolism of Opium can be decreased when combined with Cyclosporine.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Orciprenaline.]
[G04CA02, tamsulosin, The risk or severity of renal failure can be increased when Tamsulosin is combined with Cyclosporine.]
[C01AC01, ouabain, The excretion of Ouabain can be decreased when combined with Cyclosporine.]
[M05BA08, zoledronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Zoledronic acid.]
[J01CF04, oxacillin, Cyclosporine may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[A14AA08, oxandrolone, The risk or severity of liver damage can be increased when Oxandrolone is combined with Cyclosporine.]
[N05BA04, oxazepam, Cyclosporine may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[J01MB05, oxolinic acid, The risk or severity of nephrotoxicity can be increased when Oxolinic acid is combined with Cyclosporine.]
[C07AA02, oxprenolol, The metabolism of Oxprenolol can be decreased when combined with Cyclosporine.]
[N02AA05, oxycodone, The metabolism of Oxycodone can be decreased when combined with Cyclosporine.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Cyclosporine is combined with Oxymetazoline.]
[A14AA05, oxymetholone, The risk or severity of liver damage can be increased when Oxymetholone is combined with Cyclosporine.]
[N02AA11, oxymorphone, The metabolism of Oxymorphone can be decreased when combined with Cyclosporine.]
[N05AE01, oxypertine, Cyclosporine may increase the neurotoxic activities of Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of renal failure and hypertension can be increased when Oxyphenbutazone is combined with Cyclosporine.]
[S01AA04, oxytetracycline, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Oxytetracycline.]
[V04CH30, 4-aminohippuric acid, The excretion of Aminohippuric acid can be decreased when combined with Cyclosporine.]
[N05AH05, asenapine, The metabolism of Asenapine can be decreased when combined with Cyclosporine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Danaparoid.]
[M03AC01, pancuronium, The therapeutic efficacy of Pancuronium can be increased when used in combination with Cyclosporine.]
[J04AB30, capreomycin, Cyclosporine may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G03DB06, chlormadinone, The metabolism of Cyclosporine can be decreased when combined with Chlormadinone.]
[N05CC05, paraldehyde, The therapeutic efficacy of Paraldehyde can be decreased when used in combination with Cyclosporine.]
[H02AB05, paramethasone, Paramethasone may increase the immunosuppressive activities of Cyclosporine.]
[C02KC01, pargyline, Cyclosporine may decrease the antihypertensive activities of Pargyline.]
[A07AA06, paromomycin, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Paromomycin.]
[J01MA03, pefloxacin, The risk or severity of nephrotoxicity can be increased when Pefloxacin is combined with Cyclosporine.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Cyclosporine.]
[C07AA23, penbutolol, The metabolism of Penbutolol can be decreased when combined with Cyclosporine.]
[N05AG03, penfluridol, The metabolism of Penfluridol can be decreased when combined with Cyclosporine.]
[M01CC01, penicillamine, Penicillamine may increase the immunosuppressive activities of Cyclosporine.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Cyclosporine.]
[J01CE09, penicillin G procaine, Cyclosporine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.]
[N05CA01, pentobarbital, The metabolism of Cyclosporine can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Pentostatin may increase the immunosuppressive activities of Cyclosporine.]
[C04AD03, pentoxifylline, Cyclosporine may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.]
[N05AB10, perazine, Cyclosporine may increase the neurotoxic activities of Perazine.]
[N04BC02, pergolide, The risk or severity of hypertension can be increased when Cyclosporine is combined with Pergolide.]
[C08EX02, perhexiline, The metabolism of Perhexiline can be decreased when combined with Cyclosporine.]
[N05AB03, perphenazine, The metabolism of Perphenazine can be decreased when combined with Cyclosporine.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Cyclosporine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Cyclosporine.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Phenazopyridine.]
[N06AF03, phenelzine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenelzine.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Cyclosporine.]
[N03AA02, phenobarbital, The metabolism of Cyclosporine can be increased when combined with Phenobarbital.]
[C04AX02, phenoxybenzamine, Cyclosporine may decrease the antihypertensive activities of Phenoxybenzamine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Cyclosporine.]
[A08AA01, phentermine, The metabolism of Phentermine can be decreased when combined with Cyclosporine.]
[V03AB36, phentolamine, Cyclosporine may decrease the antihypertensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of renal failure and hypertension can be increased when Phenylbutazone is combined with Cyclosporine.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenylephrine.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Cyclosporine.]
[R01BA01, phenylpropanolamine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenylpropanolamine.]
[N03AB02, phenytoin, The serum concentration of Cyclosporine can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, Golimumab may increase the immunosuppressive activities of Cyclosporine.]
[S01AE05, levofloxacin, The serum concentration of Cyclosporine can be increased when it is combined with Levofloxacin.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Cyclosporine.]
[B02BA01, vitamin K1, Cyclosporine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cidofovir.]
[C08CX01, mibefradil, The serum concentration of Cyclosporine can be increased when it is combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Cyclosporine.]
[C07AA03, pindolol, The metabolism of Pindolol can be decreased when combined with Cyclosporine.]
[C10AA05, atorvastatin, The excretion of Atorvastatin can be decreased when combined with Cyclosporine.]
[J01CA12, piperacillin, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Piperacillin.]
[J05AE01, saquinavir, The metabolism of Cyclosporine can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Cyclosporine.]
[N05AC04, pipothiazine, The metabolism of Pipotiazine can be decreased when combined with Cyclosporine.]
[N06BX03, piracetam, Cyclosporine may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of hyperkalemia can be increased when Eprosartan is combined with Cyclosporine.]
[S01BC06, piroxicam, The risk or severity of renal failure and hypertension can be increased when Piroxicam is combined with Cyclosporine.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefditoren.]
[J01MA11, grepafloxacin, The risk or severity of nephrotoxicity can be increased when Grepafloxacin is combined with Cyclosporine.]
[N02CX01, pizotyline, The risk or severity of hypertension can be increased when Cyclosporine is combined with Pizotifen.]
[J05AG02, delavirdine, The metabolism of Cyclosporine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of hyperkalemia can be increased when Irbesartan is combined with Cyclosporine.]
[A10BG02, rosiglitazone, Cyclosporine may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Cyclosporine.]
[L04AC08, canakinumab, Canakinumab may increase the immunosuppressive activities of Cyclosporine.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Cyclosporine is combined with Polymyxin B.]
[C03AA05, polythiazide, The risk or severity of renal failure can be increased when Polythiazide is combined with Cyclosporine.]
[J05AE03, ritonavir, The serum concentration of Cyclosporine can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Cyclosporine can be decreased when combined with Saxagliptin.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Cyclosporine.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Cyclosporine.]
[C10AA08, pitavastatin, The serum concentration of Pitavastatin can be increased when it is combined with Cyclosporine.]
[C07AB01, practolol, The metabolism of Practolol can be decreased when combined with Cyclosporine.]
[N05BA11, prazepam, The metabolism of Prazepam can be decreased when combined with Cyclosporine.]
[P02BA01, praziquantel, The metabolism of Cyclosporine can be decreased when combined with Praziquantel.]
[C02CA01, prazosin, Cyclosporine may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[S03BA02, prednisolone, Prednisolone may increase the immunosuppressive activities of Cyclosporine.]
[H02AB07, prednisone, Prednisone may increase the immunosuppressive activities of Cyclosporine.]
[C01DX02, prenylamine, The metabolism of Prenylamine can be decreased when combined with Cyclosporine.]
[P01BA03, primaquine, The metabolism of Cyclosporine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Cyclosporine can be increased when combined with Primidone.]
[M04AB01, probenecid, The risk or severity of renal failure can be increased when Probenecid is combined with Cyclosporine.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Cyclosporine.]
[L01XB01, procarbazine, Procarbazine may increase the immunosuppressive activities of Cyclosporine.]
[C10AB05, fenofibrate, The risk or severity of renal failure can be increased when Cyclosporine is combined with Fenofibrate.]
[N05AB04, prochlorperazine, The metabolism of Prochlorperazine can be decreased when combined with Cyclosporine.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Cyclosporine.]
[N05AA03, promazine, The metabolism of Promazine can be decreased when combined with Cyclosporine.]
[G03DB07, promegestone, The metabolism of Promegestone can be decreased when combined with Cyclosporine.]
[R06AD02, promethazine, The metabolism of Promethazine can be decreased when combined with Cyclosporine.]
[C01BC03, propafenone, The metabolism of Propafenone can be decreased when combined with Cyclosporine.]
[A03AB05, propantheline, Cyclosporine may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[R06AX26, fexofenadine, The serum concentration of Fexofenadine can be increased when it is combined with Cyclosporine.]
[N05AC01, periciazine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Periciazine.]
[N05CM06, propiomazine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Propiomazine.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Cyclosporine.]
[N01AX10, propofol, The metabolism of Cyclosporine can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Dextropropoxyphene can be decreased when combined with Cyclosporine.]
[C07AA05, propranolol, The metabolism of Propranolol can be decreased when combined with Cyclosporine.]
[H03BA02, propylthiouracil, Propylthiouracil may increase the immunosuppressive activities of Cyclosporine.]
[N02CC04, rizatriptan, The risk or severity of hypertension can be increased when Cyclosporine is combined with Rizatriptan.]
[B01AC09, epoprostenol, Cyclosporine may decrease the antihypertensive activities of Epoprostenol.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Cyclosporine.]
[N06AA11, protriptyline, The risk or severity of hypertension can be increased when Cyclosporine is combined with Protriptyline.]
[R01BA02, pseudoephedrine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Cyclosporine.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Cyclosporine is combined with Dalfampridine.]
[P02CC01, pyrantel, The therapeutic efficacy of Pyrantel can be increased when used in combination with Cyclosporine.]
[J04AK01, pyrazinamide, The serum concentration of Cyclosporine can be decreased when it is combined with Pyrazinamide.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Cyclosporine.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Cyclosporine.]
[P01AX05, quinacrine, The metabolism of Cyclosporine can be decreased when combined with Quinacrine.]
[C01BA01, quinidine, The serum concentration of Quinidine can be increased when it is combined with Cyclosporine.]
[P01BC01, quinine, The metabolism of Quinine can be decreased when combined with Cyclosporine.]
[D07AC10, diflorasone, The risk or severity of adverse effects can be increased when Diflorasone is combined with Cyclosporine.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Ranitidine.]
[C02AA01, rescinnamine, Cyclosporine may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The serum concentration of Cyclosporine can be increased when it is combined with Reserpine.]
[J05AP01, ribavirin, Cyclosporine may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[J04AB02, rifampin, The serum concentration of Cyclosporine can be decreased when it is combined with Rifampicin.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Cyclosporine is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Ritodrine.]
[J01AA09, rolitetracycline, The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Rolitetracycline.]
[J01FA06, roxithromycin, The metabolism of Cyclosporine can be decreased when combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of renal failure and hypertension can be increased when Salicylamide is combined with Cyclosporine.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the immunosuppressive activities of Cyclosporine.]
[S01BC08, salicylic acid, The risk or severity of renal failure and hypertension can be increased when Salicylic acid is combined with Cyclosporine.]
[S01FA02, scopolamine, The metabolism of Scopolamine can be decreased when combined with Cyclosporine.]
[N05CA06, secobarbital, The metabolism of Cyclosporine can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Cyclosporine.]
[L01FA03, obinutuzumab, Obinutuzumab may increase the immunosuppressive activities of Cyclosporine.]
[V04CC03, sincalide, The excretion of Sincalide can be decreased when combined with Cyclosporine.]
[J01GB08, sisomicin, Cyclosporine may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Cyclosporine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[M05BX04, denosumab, Denosumab may increase the immunosuppressive activities of Cyclosporine.]
[H01CB01, somatostatin, The bioavailability of Cyclosporine can be decreased when combined with Somatostatin.]
[V04CC01, sorbitol, Cyclosporine may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Cyclosporine.]
[L01CD04, cabazitaxel, Cabazitaxel may increase the immunosuppressive activities of Cyclosporine.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclosporine.]
[C03DA01, spironolactone, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cyclosporine.]
[V04CH02, indigo carmine, Cyclosporine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[N05CC01, chloral hydrate, Cyclosporine may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[N03AG01, valproic acid, The metabolism of Cyclosporine can be decreased when combined with Valproic acid.]
[A05AA01, chenodeoxycholic acid, The metabolism of Chenodeoxycholic acid can be decreased when combined with Cyclosporine.]
[M05BA01, etidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Etidronic acid.]
[M05BA04, alendronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Alendronic acid.]
[D07AB02, hydrocortisone butyrate, Hydrocortisone butyrate may increase the immunosuppressive activities of Cyclosporine.]
[D07AB11, hydrocortisone probutate, The risk or severity of adverse effects can be increased when Hydrocortisone probutate is combined with Cyclosporine.]
[C01DA14, isosorbide mononitrate, Cyclosporine may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[H02CA04, levoketoconazole, The metabolism of Cyclosporine can be decreased when combined with Levoketoconazole.]
[D10AX03, azelaic acid, Cyclosporine may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[A05AA02, ursodiol, Cyclosporine may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
